<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">76228</article-id><article-id pub-id-type="doi">10.7554/eLife.76228</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Modeling osteoporosis to design and optimize pharmacological therapies comprising multiple drug types</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-263463"><name><surname>Jörg</surname><given-names>David J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5960-0260</contrib-id><email>david.joerg@fmc-ag.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-263521"><name><surname>Fuertinger</surname><given-names>Doris H</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6321-2367</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-263522"><name><surname>Cherif</surname><given-names>Alhaji</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-162570"><name><surname>Bushinsky</surname><given-names>David A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-263523"><name><surname>Mermelstein</surname><given-names>Ariella</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-263524"><name><surname>Raimann</surname><given-names>Jochen G</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-263525"><name><surname>Kotanko</surname><given-names>Peter</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4373-412X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf7"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04sk0bj73</institution-id><institution>Biomedical Modeling and Simulation Group, Global Research and Development, Fresenius Medical Care Germany</institution></institution-wrap><addr-line><named-content content-type="city">Bad Homburg</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032g46r36</institution-id><institution>Renal Research Institute</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00trqv719</institution-id><institution>Department of Medicine, University of Rochester School of Medicine and Dentistry</institution></institution-wrap><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Napoli</surname><given-names>Nicola</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gqx4x78</institution-id><institution>Campus Bio-Medico University of Rome</institution></institution-wrap><country>Italy</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>09</day><month>08</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e76228</elocation-id><history><date date-type="received" iso-8601-date="2021-12-08"><day>08</day><month>12</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-06-26"><day>26</day><month>06</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-12-20"><day>20</day><month>12</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.12.17.473190"/></event></pub-history><permissions><copyright-statement>© 2022, Jörg et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Jörg et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-76228-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-76228-figures-v1.pdf"/><abstract><p>For the treatment of postmenopausal osteoporosis, several drug classes with different mechanisms of action are available. Since only a limited set of dosing regimens and drug combinations can be tested in clinical trials, it is currently unclear whether common medication strategies achieve optimal bone mineral density gains or are outperformed by alternative dosing schemes and combination therapies that have not been explored so far. Here, we develop a mathematical framework of drug interventions for postmenopausal osteoporosis that unifies fundamental mechanisms of bone remodeling and the mechanisms of action of four drug classes: bisphosphonates, parathyroid hormone analogs, sclerostin inhibitors, and receptor activator of NF-κB ligand inhibitors. Using data from several clinical trials, we calibrate and validate the model, demonstrating its predictive capacity for complex medication scenarios, including sequential and parallel drug combinations. Via simulations, we reveal that there is a large potential to improve gains in bone mineral density by exploiting synergistic interactions between different drug classes, without increasing the total amount of drug administered.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Our bones are constantly being renewed in a fine-tuned cycle of destruction and formation that helps keep them healthy and strong. However, this process can become imbalanced and lead to osteoporosis, where the bones are weakened and have a high risk of fracturing. This is particularly common post-menopause, with one in three women over the age of 50 experiencing a broken bone due to osteoporosis.</p><p>There are several drug types available for treating osteoporosis, which work in different ways to strengthen bones. These drugs can be taken individually or combined, meaning that a huge number of drug combinations and treatment strategies are theoretically possible. However, it is not practical to test the effectiveness of all of these options in human trials. This could mean that patients are not getting the maximum potential benefit from the drugs available.</p><p>Jörg et al. developed a mathematical model to predict how different osteoporosis drugs affect the process of bone renewal in the human body. The model could then simulate the effect of changing the order in which the therapies were taken, which showed that the sequence had a considerable impact on the efficacy of the treatment. This occurs because different drugs can interact with each other, leading to an improved outcome when they work in the right order.</p><p>These results suggest that people with osteoporosis may benefit from altered treatment schemes without changing the type or amount of medication taken. The model could suggest new treatment combinations that reduce the risk of bone fracture, potentially even developing personalised plans for individual patients based on routine clinical measurements in response to different drugs.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>osteoporosis</kwd><kwd>pharmacodynamics</kwd><kwd>mathematical model</kwd><kwd>combination therapy</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><funding-statement>No external funding was received for this work.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A mathematical model of osteoporosis explains why the sequence of osteoporosis medications matters for short-term and long-term treatment success.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Osteoporosis, a disease characterized by porous bone prone to fractures, affects hundreds of millions of people worldwide (<xref ref-type="bibr" rid="bib16">Cooper and Ferrari, 2019</xref>; <xref ref-type="bibr" rid="bib28">Hernlund et al., 2013</xref>). Most recent estimates place the global annual incidence of bone fragility fractures at 9 million in the year 2000 (<xref ref-type="bibr" rid="bib16">Cooper and Ferrari, 2019</xref>); projections for the year 2050 suggest between 7 and 21 million annual hip fractures (<xref ref-type="bibr" rid="bib25">Gullberg et al., 1997</xref>). Osteoporosis-associated bone fractures lead to disabilities, pain, and increased mortality (<xref ref-type="bibr" rid="bib16">Cooper and Ferrari, 2019</xref>). In the United States, medical cost for osteoporosis, including inpatient, outpatient, and long-term care costs, has been estimated at US$17 billion in 2005 (<xref ref-type="bibr" rid="bib14">Burge et al., 2007</xref>); in the European Union, the total cost of osteoporosis, including pharmacological interventions and loss of quality-adjusted life-years (QALYs), is projected to rise from about €100 billion in 2010 to €120 billion in 2025 (<xref ref-type="bibr" rid="bib64">Odén et al., 2013</xref>).</p><p>Osteoporotic bone is the consequence of an imbalance of continuous bone resorption and bone formation, which—under close to homeostatic conditions—has the function to remove microfractures and renew the structural integrity of bone. Postmenopausal women are particularly at risk of osteoporosis: the rapid decline of systemic estrogen levels after menopause and other aging-related effects such as increased oxidative stress contribute to or drive the development of osteoporosis (<xref ref-type="bibr" rid="bib73">Riggs et al., 1998</xref>; <xref ref-type="bibr" rid="bib54">Manolagas, 2010</xref>). Moreover, osteoporosis can be a sequela of diseases affecting bone metabolism and remodeling such as primary hyperparathyroidism or gastrointestinal diseases (<xref ref-type="bibr" rid="bib67">Painter et al., 2006</xref>). Osteoporosis can also be a side effect of treatments for other diseases; as a prime example, glucocorticoid administration is the most common cause of secondary osteoporosis (<xref ref-type="bibr" rid="bib96">Weinstein, 2012</xref>). Over the last decades, an array of different osteoporosis treatments have emerged, from simple dietary supplementations such as calcium and vitamin D to specialized drugs targeting bone-forming and -resorbing cells and related signaling pathways (<xref ref-type="bibr" rid="bib94">Tu et al., 2018</xref>). This entails a plethora of different medication options, including a large number of possible dosing schemes and combinations of drugs, administered in sequence or in parallel. Due to the huge number of such treatment schemes and the required time from study inception to completion, very few of them have been clinically tested so far when compared to the total number of available options.</p><p>Concomitant with the development of new osteoporosis drugs, mathematical and biophysical modeling approaches capturing bone-related physiology have advanced our quantitative understanding of the biological principles governing bone mineral metabolism, bone turnover, and development of osteoporosis. Pioneering work by <xref ref-type="bibr" rid="bib45">Lemaire et al., 2004</xref> describes the dynamics of bone-forming and -resorbing cell populations coupled through signaling pathways and could qualitatively reproduce the effects of senescence, glucocorticoid excess, and estrogen and vitamin D deficiency on bone turnover. Since then, compartment-based descriptions of the mineral metabolism, bone-forming and -resorbing cell populations, and related signaling factors have elucidated the role of essential regulatory mechanisms underlying mineral balance and bone turnover (<xref ref-type="bibr" rid="bib38">Komarova et al., 2003</xref>; <xref ref-type="bibr" rid="bib45">Lemaire et al., 2004</xref>; <xref ref-type="bibr" rid="bib69">Pivonka et al., 2008</xref>; <xref ref-type="bibr" rid="bib70">Pivonka et al., 2010</xref>; <xref ref-type="bibr" rid="bib68">Peterson and Riggs, 2010</xref>; <xref ref-type="bibr" rid="bib100">Zumsande et al., 2011</xref>; <xref ref-type="bibr" rid="bib84">Schmidt et al., 2011</xref>; <xref ref-type="bibr" rid="bib24">Graham et al., 2013</xref>; <xref ref-type="bibr" rid="bib92">Tanaka et al., 2014</xref>; <xref ref-type="bibr" rid="bib39">Komarova et al., 2015</xref>; <xref ref-type="bibr" rid="bib6">Berkhout et al., 2015</xref>). Coarse-grained as well as detailed spatially extended descriptions of bone geometry have also addressed the effects of mechanical forces and the propagation of the multicellular units responsible for bone turnover (<xref ref-type="bibr" rid="bib78">Ryser et al., 2009</xref>; <xref ref-type="bibr" rid="bib12">Buenzli et al., 2011</xref>; <xref ref-type="bibr" rid="bib82">Scheiner et al., 2013</xref>; <xref ref-type="bibr" rid="bib13">Buenzli et al., 2014</xref>; <xref ref-type="bibr" rid="bib71">Pivonka et al., 2013</xref>), as well as the influence of secondary diseases such as multiple myeloma (<xref ref-type="bibr" rid="bib3">Ayati et al., 2010</xref>). Detailed models of bone remodeling and calcium homeostasis have become versatile and widely used tools in hypothesis testing, such as the seminal model by <xref ref-type="bibr" rid="bib68">Peterson and Riggs, 2010</xref>, which includes submodels for various organs such as gut, kidney, and the parathyroid gland. Pharmacokinetic and pharmacodynamic (PK/PD) models of therapeutic interventions have mostly focused on capturing the mechanisms of action of a single or a few drugs and testing their dosing regimens (<xref ref-type="bibr" rid="bib55">Marathe et al., 2008</xref>; <xref ref-type="bibr" rid="bib56">Marathe et al., 2011</xref>; <xref ref-type="bibr" rid="bib75">Ross et al., 2012</xref>; <xref ref-type="bibr" rid="bib83">Scheiner et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Eudy et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Lisberg et al., 2017</xref>; <xref ref-type="bibr" rid="bib58">Martínez-Reina and Pivonka, 2019</xref>; <xref ref-type="bibr" rid="bib99">Zhang and Mager, 2019</xref>). Recent modeling efforts have also started addressing the effects of drug combinations on bone-forming and -resorbing cells, pointing out the need for corresponding model frameworks to include clinically relevant variables like bone mineral density (BMD) and bone turnover biomarkers (BTMs) (<xref ref-type="bibr" rid="bib46">Lemaire and Cox, 2019</xref>), as well as combination therapies of physical exercise and drug treatment (<xref ref-type="bibr" rid="bib42">Lavaill et al., 2020</xref>). An integrated mathematical framework for multiple drugs, which can also be used to quantitatively predict the effects of drug combinations in sequence and in parallel is not yet available.</p><p>Building on established mechanisms of bone turnover, we here present a quantitative model of bone turnover and postmenopausal osteoporosis treatment, unifying the description of multiple classes of drugs with different mechanisms of action, namely, bisphosphonates, parathyroid hormone (PTH) analogs, sclerostin antibodies, and receptor activator of NF-<inline-formula><mml:math id="inf1"><mml:mi>κ</mml:mi></mml:math></inline-formula>B ligand (RANKL) antibodies. We calibrate the model using published population-level data from several clinical trials and assess its ability to predict the outcome of previously conducted clinical studies based on the medication scheme alone. We then use the model to demonstrate how medication schemes involving drug combinations can be optimized for a given medication load and discuss future model extensions.</p><sec id="s1-1"><title>Mechanisms of bone turnover and its regulation</title><p>Our model is based on a small set of key principles of bone turnover, which we briefly recapitulate here (<xref ref-type="fig" rid="fig1">Figure 1</xref>). As a composite tissue comprising hydroxyapatite, collagen, other proteins, and water (<xref ref-type="bibr" rid="bib10">Boskey, 2013</xref>), bone is constantly turned over to renew its integrity and remove microdamage, at an average rate of about 4% per year in cortical bone and about 30% per year in trabecular bone (<xref ref-type="bibr" rid="bib53">Manolagas, 2000</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Schematic of the osteoporosis model describing the cell dynamics and signaling pathways within a ‘representative bone remodeling unit (BRU)’.</title><p>Regulatory interactions between different model components are indicated by colored boxes (see legend). TGFβ, transforming growth factor beta; BMP, bone morphogenetic protein; PDGF, platelet-derived growth factor; IGF, insulin-like growth factor; FGF, fibroblast growth factor.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76228-fig1-v1.tif"/></fig><sec id="s1-1-1"><title>Bone-resorbing and -forming cells</title><p>Bone resorption is performed by osteoclasts, multinucleated cells formed through the differentiation and fusion of their immediate precursors (pre-osteoclasts), which are derived from pluripotent hematopoietic stem cells via the myeloid lineage (<xref ref-type="bibr" rid="bib11">Boyce and Xing, 2008</xref>). Osteoclasts attach to bone tissue and resorb it through the secretion of hydrogen ions and bone-degrading enzymes (<xref ref-type="bibr" rid="bib22">Fuller and Chambers, 1995</xref>), which leads to the release of minerals and signaling factors stored in the bone matrix. New bone is formed by osteoblasts, a cell type derived from mesenchymal stem cells via several intermediate states that give rise to pre-osteoblasts and finally osteoblasts (<xref ref-type="bibr" rid="bib20">Eriksen, 2010</xref>). Groups of osteoblasts organize into cell clusters (osteons) and collectively lay down an organic matrix (osteoid), which subsequently becomes mineralized over the course of months. Osteoblasts that are enclosed in the newly secreted bone matrix become osteocytes, nondividing cells with an average life span of up to several decades. Osteoclasts and osteoblasts organize into spatially defined local clusters termed ‘bone remodeling units’ (BRUs) (<xref ref-type="fig" rid="fig1">Figure 1</xref>), in which osteoblasts replenish the bone matrix previously resorbed by osteoclasts with a delay of several weeks. In cortical bone, the outer protective bone layer, BRUs migrate as a whole in ‘tunnels,’ whereas within the inner cancellous bone, BRUs propagate on the surfaces of the trabeculae, renewing the bone matrix in the process (<xref ref-type="bibr" rid="bib20">Eriksen, 2010</xref>).</p></sec><sec id="s1-1-2"><title>Signaling pathways</title><p>The differentiation and activity of osteoclasts and osteoblasts are regulated through several signaling pathways and hormones; recent reviews provide comprehensive descriptions of the various pathways (<xref ref-type="bibr" rid="bib85">Siddiqui and Partridge, 2016</xref>). Osteoclast formation and activity are prominently regulated by RANKL and macrophage colony-stimulating factor (M-CSF) synthesized by bone marrow stromal cells. RANKL binds to receptor activator of NF-<inline-formula><mml:math id="inf2"><mml:mi>κ</mml:mi></mml:math></inline-formula>B (RANK) on osteoclast precursors and promotes their differentiation into mature osteoclasts; osteoprotegerin (OPG) acts as a decoy receptor for RANKL and thus inhibits bone resorption (<xref ref-type="bibr" rid="bib11">Boyce and Xing, 2008</xref>; <xref ref-type="bibr" rid="bib15">Clarke, 2008</xref>). When laying down new bone, osteoblasts store signaling factors in the bone matrix, including transforming growth factor beta (TGFβ), bone morphogenetic protein (BMP), insulin growth factors (IGFs), platelet-derived growth factor (PDGF), and fibroblast growth factors (FGFs) (<xref ref-type="bibr" rid="bib86">Solheim, 1998</xref>). Upon bone resorption, these factors are released and regulate cell fates and activity of osteoblasts and osteoclasts, thereby coupling bone resorption and formation (<xref ref-type="bibr" rid="bib30">Houde et al., 2009</xref>; <xref ref-type="bibr" rid="bib20">Eriksen, 2010</xref>). Osteocytes secrete sclerostin, a Wnt inhibitor interfering with extracellular binding of Wnt ligands (<xref ref-type="bibr" rid="bib48">Li et al., 2005</xref>). Sclerostin inhibits bone formation and promotes resorption via downregulation of osteoblastogenesis and upregulation of osteoclastogenesis (<xref ref-type="bibr" rid="bib18">Delgado-Calle et al., 2017</xref>; <xref ref-type="bibr" rid="bib57">Maré et al., 2020</xref>). Since bone also acts as a mineral reservoir for the body, regulators of calcium homeostasis such as PTH and vitamin D also strongly affect the balance of bone formation and resorption alongside the intestinal absorption and renal reabsorption of calcium (<xref ref-type="bibr" rid="bib63">Mundy and Guise, 1999</xref>).</p></sec><sec id="s1-1-3"><title>Estrogen</title><p>The sex hormone estrogen inhibits bone resorption by inducing apoptosis of osteoclasts (<xref ref-type="bibr" rid="bib34">Kameda et al., 1997</xref>) and lowering circulating sclerostin levels (<xref ref-type="bibr" rid="bib62">Mödder et al., 2011</xref>). The rapid decline of estrogen levels after menopause is one known cause of postmenopausal osteoporosis (<xref ref-type="bibr" rid="bib73">Riggs et al., 1998</xref>).</p></sec></sec></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Model overview</title><p>The primary purpose of our model is to provide an efficient representation of bone turnover on multiple time scales from weeks to decades that allows for the quantitative description of drug interventions. Of particular interest are the consequences of pharmacological therapies on long-term dynamics of the BMD in specific bone sites and biochemical markers of bone formation and resorption. To this end, we considered a minimal set of physiologically relevant dynamic components (<xref ref-type="fig" rid="fig1">Figure 1</xref>) that are sufficient to capture a large range of clinically observed population-level data on drug interventions. Thus, our model describes a ‘representative BRU’ that abstracts from the vast set of intricate regulatory mechanisms underlying calcium homeostasis or the complex bone geometry.</p><p>Our model comprises the following dynamic components to describe the bone turnover through a representative BRU: cell densities of (i) pre-osteoclasts, (ii) osteoclasts, (iii) pre-osteoblasts, (iv) osteoblasts, (v) osteocytes, (vi) sclerostin concentration, (vii) total bone density, and (viii) bone mineral content (BMC). The BMD is given by the product of bone density and BMC. Osteoblasts and osteoclasts can undergo apoptosis and are derived from pre-osteoblasts and pre-osteoclasts, respectively, with differentiation rates that depend on regulatory factors such as estrogen and sclerostin (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Pre-osteoblasts and pre-osteoclasts are formed at constant rates and undergo apoptosis. These progenitor populations provide a dynamic reservoir for rapid differentiation and activation of osteoblasts and osteoclasts, respectively, which can be temporarily depleted if stimulated by a drug intervention. Osteocytes are derived from osteoblasts and provide a source of sclerostin, which has a regulatory effect on osteoblasts, osteoclasts, and thus, bone density change. The gain and loss rates of bone density are proportional to the density of osteoblasts and osteoclasts, respectively. The BMC has a steady state whose level can be temporarily shifted through drug administration, effectively accounting for more complex underlying dynamics such as promotion of secondary mineralization. All rates of cell formation, differentiation, apoptosis, and bone formation and resorption generally depend on the concentration of sclerostin, estrogen, and a ‘resorption signal.’ These dependencies also implicitly account for regulation of bone remodeling via other routes, for example, the RANK–RANKL–OPG pathway. The effects of aging and the onset of menopause are represented through an age-dependent serum estrogen concentration, which has been determined from the literature (<xref ref-type="bibr" rid="bib88">Sowers et al., 2008</xref>; Appendix 1). The resorption signal corresponds to the melange of signaling factors stored in the bone matrix. Therefore, its release is proportional to the rate of bone resorption. The serum concentration of BTMs such as the resorption marker C-terminal telopeptide (CTX), the formation markers procollagen type 1 amino-terminal propeptide (P1NP), and bone-specific alkaline phosphatase (BSAP) were identified with elementary functions of the bone resorption and formation rates in the model (Appendix 1).</p><p>We extended this core model of long-term bone turnover by a dynamic description of the mechanisms of action of several drug classes used in osteoporosis treatment: RANKL antibodies (denosumab), sclerostin antibodies (romosozumab), bisphosphonates (alendronate and others), and PTH analogs (teriparatide) (Appendix 2). We also included blosozumab, another sclerostin inhibitor, which was investigated in osteoporosis trials but not approved for osteoporosis treatment at the time the present work was conducted. PTH is known to exert anabolic or catabolic effects depending on whether administration is intermittent or continuous (<xref ref-type="bibr" rid="bib91">Tam et al., 1982</xref>; <xref ref-type="bibr" rid="bib29">Hock and Gera, 1992</xref>); PTH description in our model is restricted to the anabolic administration regimes relevant for osteoporosis treatment. A schematic overview of all model components, mechanisms, and regulatory interactions is given in <xref ref-type="fig" rid="fig1">Figure 1</xref>; a detailed formal description of the model and its extensions is provided in Appendix 1 and Appendix 2.</p></sec><sec id="s2-2"><title>Capturing clinical study results with the model</title><p>The model and the corresponding medication modules rely on an array of physiological parameters (rates of cell formation, differentiation and death, concentration thresholds for signaling activity, medication efficacies and half-lives, etc.) many of which are not directly measureable. However, clinical measurements on physiological responses to medications with different mechanisms of action provide a wealth of indirect information about time scales of bone turnover and regulatory feedbacks. We calibrated the model using published clinical data from various seminal studies on both (i) long-term BMD age dependence and (ii) the response of BMD and BTMs to the administration of different drugs (see <xref ref-type="table" rid="app3table2">Appendix 3—table 2</xref> for a comprehensive list of data sources). Although BMD constitutes the major target variable of our model, the dynamics of BTM concentrations carry important complementary information about the mode of action of the administered drugs (antiresorptive, anabolic, and combinations) that crucially informs the calibration procedure. To allow the model to capture the effects of medications as physiologically sensible modulations of the age-dependent bone mineral metabolism, we created hybrid datasets each of which comprised both aging-related BMD changes and the response to a treatment (see ‘Methods’ and <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1D</xref>).</p><p>We then determined a single set of model parameters through a simultaneous fit of the free 31 model parameters to capture a specified set of hybrid aging/treatment datasets containing different drug responses (Appendix 3). Without constraining the average rate of skeletal bone turnover, model calibration yielded an inferred value of about 6% per year on average, of the same order of values reported for cortical bone, which constitutes about 75% of the skeleton (<xref ref-type="bibr" rid="bib53">Manolagas, 2000</xref>). The model was able to capture the BMD and BTM dynamics across all calibration datasets with remarkable accuracy (<xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1</xref>), despite the model’s structural simplicity. To quantify the goodness of the fit, we computed the mean absolute percentage error (MAPE) between model simulations and clinical data; the MAPE for BMD was consistently below 1% for all calibration datasets (<xref ref-type="table" rid="app3table3">Appendix 3—table 3</xref>), indicating an excellent agreement between model and data. The qualitative behavior of BTMs (i.e., the direction of their excursions from baseline) was captured correctly in all calibration datasets, indicating an adequate description of the drugs’ mode of action in the model; relative deviations in the total magnitude of BTM excursions observed for some datasets were mostly due to slight offsets in the timing of peaks and troughs and low absolute values of the respective BTM concentrations, as highlighted by comparing different goodness measures (Appendix 3 and <xref ref-type="table" rid="app3table3">Appendix 3—table 3</xref>).</p><p>After obtaining the reference parameter set, we sought to validate the calibrated model by assessing its ability to predict the effects of drug dosing schemes that had not been used for calibration. Model validation included complex sequential and parallel drug combinations and therefore challenged the model to predict the effects of treatment schemes beyond those used in calibration (<xref ref-type="table" rid="app3table2">Appendix 3—table 2</xref>). To this end, the model received only drug dosing information used in the respective clinical trials but was not informed by BMD or BTM measurements, which instead it had to predict. With the single set of previously determined parameters, the model showed a remarkable capacity to quantitatively forecast the effects of a multitude of medication schemes, both during treatment and follow-up periods (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Even in scenarios including sequential treatments with up to three different drug types and parallel treatments with two different drugs, respectively, the model was able to predict the complex progression of both BMD and biomarker levels with a high degree of accuracy (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Across all validation datasets, MAPEs for BMD were consistently below 1.5% (<xref ref-type="table" rid="app3table3">Appendix 3—table 3</xref>), indicating an excellent predictive capacity of the model. In summary, this validation provided a strong corroboration of the model’s capacity to capture the physiological dynamics of bone turnover and the mechanisms of action of various drugs relevant to osteoporosis treatment using a single set of model parameters.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>With a single set of parameters, the calibrated model can quantitatively predict the effects of various drugs in different dosing regimens, alone and in combination.</title><p>(<bold>A</bold>) Comparison of simulated total hip bone mineral density (BMD, black curves) and clinical data (dots), including aging behavior (green dots) and treatment behavior (black dots) of various sequential drug treatments, including denosumab, romosozumab, alendronate, and teriparatide. Hybrid aging/treatment datasets were created combining data from <xref ref-type="bibr" rid="bib52">Looker et al., 1998</xref> (aging dataset, green dots in panel <bold>A</bold>; in total <inline-formula><mml:math id="inf3"><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>3251</mml:mn></mml:mrow></mml:math></inline-formula> subjects 20 years and older), as well as <xref ref-type="bibr" rid="bib72">Recknor et al., 2015</xref> (blosozumab 180 mg Q2W: <inline-formula><mml:math id="inf4"><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>25</mml:mn></mml:mrow></mml:math></inline-formula>), <xref ref-type="bibr" rid="bib61">McClung et al., 2018</xref> (placebo/deno.: <inline-formula><mml:math id="inf5"><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>18</mml:mn></mml:mrow></mml:math></inline-formula>, alendro./romo./deno.: <inline-formula><mml:math id="inf6"><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>21</mml:mn></mml:mrow></mml:math></inline-formula>), and <xref ref-type="bibr" rid="bib44">Leder et al., 2015</xref> (deno./teri.: <inline-formula><mml:math id="inf7"><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>27</mml:mn></mml:mrow></mml:math></inline-formula>, teri. + deno./deno.: <inline-formula><mml:math id="inf8"><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>23</mml:mn></mml:mrow></mml:math></inline-formula>) (treatment datasets, black dots in panels <bold>A </bold>and <bold>B</bold>) as indicated, see ‘Methods.’ (<bold>B</bold>) Zoom into the treatment regions shown in panel (<bold>A</bold>) including BMD (black) and baseline changes of the bone resorption marker C-terminal telopeptide (CTX, red) and the bone formation marker procollagen type 1 amino-terminal propeptide (P1NP, blue). Colored bars above the plots indicate the medication scheme (see legend). Data points show population averages; average types and error bar types as reported in the respective original publication. In both panels, BMD is displayed as a fraction of its value at <inline-formula><mml:math id="inf9"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>25</mml:mn></mml:mrow></mml:math></inline-formula> years.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76228-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Continuation of <xref ref-type="fig" rid="fig2">Figure 2</xref> comparing model predictions and clinical data from various studies, all conventions identical.</title><p>See <xref ref-type="table" rid="app3table2">Appendix 3—table 2</xref> for a list of data sources and <xref ref-type="table" rid="app3table3">Appendix 3—table 3</xref> for goodness-of-fit measures. Dosing: mg, milligrams; mcg, micrograms; Q <inline-formula><mml:math id="inf10"><mml:mi>x</mml:mi></mml:math></inline-formula> M, dose administered every <inline-formula><mml:math id="inf11"><mml:mi>x</mml:mi></mml:math></inline-formula> months; Q <inline-formula><mml:math id="inf12"><mml:mi>x</mml:mi></mml:math></inline-formula> W, every <inline-formula><mml:math id="inf13"><mml:mi>x</mml:mi></mml:math></inline-formula> weeks; Q <inline-formula><mml:math id="inf14"><mml:mi>x</mml:mi></mml:math></inline-formula> D, every <inline-formula><mml:math id="inf15"><mml:mi>x</mml:mi></mml:math></inline-formula> days; R, romosozumab; A, alendronate; D, denosumab; T, teriparatide.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76228-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Testing alternative treatment schemes</title><p>Having established the predictive capacity of the model for the considered medications, we aimed to utilize the model to study and optimize hypothetic drug dosing regimens. As an example, we considered a sequential treatment with three drugs of different types: the bisphosphonate alendronate, the sclerostin inhibitor romosozumab, and the RANKL inhibitor denosumab. In a clinical trial reported by <xref ref-type="bibr" rid="bib61">McClung et al., 2018</xref>, the sequence alendronate (70 mg per week for 1 year), followed by romosozumab (140 mg per month for 1 year), followed by denosumab (60 mg per 6 months for 1 year) had been studied (<xref ref-type="fig" rid="fig2">Figure 2</xref>). However, in principle there are six different sequences in which these drugs can be administered: ARD, ADR, DAR, DRA, RAD, and RDA (A: alendronate; R: romosozumab; D: denosumab). A priori, it is not obvious whether synergistic or antagonistic interactions between these drugs and the physiological state in which they leave the patient may lead to a differential short- and long-term evolution of BMD and biomarkers between different medication sequences. Probing all six sequences in a clinical trial would present a time- and resource-consuming endeavor and inevitably expose part of the study population to suboptimal treatment schemes. Instead, we probed these different treatment options using the present model (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). To assess the predicted clinical success of different sequences, we compared two clinically relevant outcomes across different schemes: (i) the maximum achieved BMD increase (as compared to baseline at treatment start) irrespective of when it occurred (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) and (ii) the residual long-term effects of treatment on BMD as monitored by the relative BMD 10 years after treatment end (<xref ref-type="fig" rid="fig3">Figure 3C</xref>) .</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The model predicts differential outcomes for different sequences of the same drugs at constant total medication load.</title><p>(<bold>A</bold>) Simulated progression of bone mineral density (BMD) and C-terminal telopeptide (CTX) and procollagen type 1 amino-terminal propeptide (P1NP) concentrations for different sequences (columns) of the three drugs denosumab (D), alendronate (A), and romosozumab (R) as indicated. Simulated treatment starts at age 67. The total amount of drug administered is identical among columns. Clinical results on the sequence ARD (column 5) were reported in <xref ref-type="bibr" rid="bib61">McClung et al., 2018</xref>, see also <xref ref-type="fig" rid="fig2">Figure 2</xref>. (<bold>B</bold>) Maximum simulated BMD (relative to baseline at treatment start) achieved during the course of treatment for different drug sequences. (<bold>C</bold>) Simulated BMD 10 years after treatment end (relative to baseline at treatment start) for different drug sequences.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76228-fig3-v1.tif"/></fig><p>Indeed, we found that the outcomes of different medication sequences were markedly different despite the same total amount of drug administered (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Some sequences (such as ARD and RAD) reached a considerably higher maximum BMD during the course of the simulated treatment, which allowed us to rank treatments according to maximum BMD gain (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Notably, while some sequences were superior to others as measured by the maximum BMD increase during treatment, they performed markedly worse (as compared to, e.g., DRA and RDA) with regard to long-term BMD evolution as predicted by model simulations (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). This behavior suggests that short-term BMD gains may be limited as a proxy for the clinical benefit of a treatment as a whole. Within our modeling scheme, the explanation for this behavior is found in differing ‘rebound’ effects after treatment end: simulated drug-mediated inhibition of osteoclastogenesis leads to a build-up of an undifferentiated osteoclast precursor pool. After treatment end, this precursor pool becomes licensed to differentiate and rapidly gives rise to a large active osteoclast population, leading to accelerated resorption of the bone matrix that had been built up during treatment. In this paradigm, specific drug sequences lead to an attenuation of this effect, for example, by enhancing osteoclast apoptosis during such a ‘rebound’ phase, thereby modulating bone turnover in the long run.</p><p>In summary, our model analysis suggests considerable potential in the improvement of dosing regimens and drug sequencing in osteoporosis treatment, especially combination therapies, to achieve an optimal effect for a given medication load. These improvements are possible because the mechanisms of action of one drug may act either favorably or adversely on the state of the bone mineral metabolism left behind by the preceding treatment with another drug.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Treatment of osteoporosis is complex, expensive, and in many circumstances opinion-based. With bone physiology as our guiding principle, we have introduced a mathematical modeling framework that can quantitatively capture and predict the progression of osteoporosis in postmenopausal women with and without medical therapy. Our model is built on a small set of essential mechanisms of bone turnover. The effectivity of this approach suggests that—despite the complexity of the bone mineral metabolism—the dynamics relevant for osteoporosis medications can be condensed into only a few components. These components describe the biology of osteoblasts, osteoclasts, and osteocytes, as well as their precursor cell populations and a few essential regulatory feedbacks through hormones and signaling factors such as estrogen, sclerostin, and bone-matrix-derived factors.</p><p>The general nature of the model allowed us to capture the BMD and BTMs of a multitude of clinical treatment studies. Notably, the model can also predict the effects of a broad range of drug dosing regimens and complex drug combination therapies beyond those used for model development. This corroborates the model’s predictive capacity, supporting its use for the design of future clinical trials. However, it is important to note that some parameters (e.g., concentration thresholds for signaling factors) were inferred through the model calibration procedure from BMD and BTM dynamics alone. Hence, when used as a predictive tool, general quantitative limitations of the model have to be considered, especially when extrapolating into extreme dosing regimens, dosing frequencies, or age regions beyond the validated ones.</p><p>It is of clinical relevance that exemplary model predictions suggest a large potential for the development of optimized combination therapies involving different drug types and treatment schemes. These may range from a simple rearrangement of a sequence of drugs at given total drug doses (as shown in this article) to complex interwoven or cyclic administration schemes that exploit synergistic effects between different medication types. Notably, model simulations extrapolating the long-term BMD development after treatment end suggest that medication schemes eliciting a rapid BMD increase are not necessarily accompanied by a sustained elevation of the BMD. Instead, some initially successful treatment schemes may lead to a ‘rebound’ effect of accelerated bone loss after treatment end, a prediction that cautions against using short-term BMD increases as the sole proxy for treatment success. Such extrapolations into follow-up periods long after treatment end, which are mostly inaccessible to clinical studies, highlight the potential role of the model in considering long-term treatment success when optimizing treatment schemes.</p><p>In our research, we have focused on postmenopausal osteoporosis, the most widespread type of osteoporosis. However, the generic manner in which the model represents bone remodeling and the effects of medications renders it a general platform for the study of treatments that can be adapted to other types of primary and secondary osteoporosis. The modular nature of the model enables future extensions; besides additional medication types, these may include the effects of comorbidities that elicit osteoporosis or interact with it (such as primary and secondary hyperparathyroidism), medications that contribute to osteoporosis (such as glucocorticoid therapy), lifestyle-dependent factors such as smoking and alcohol consumption, the effects of dietary supplementation of osteoporosis treatment through calcium and vitamin D and effects of microgravity on bone, as experienced by astronauts on extended missions in space. Physical activity is another important contributor to bone remodeling, which we have not considered here. Detailed modeling approaches involving biomechanical feedback suggest synergistic effects between drug treatment of osteoporosis and physical activity (<xref ref-type="bibr" rid="bib42">Lavaill et al., 2020</xref>). Such results call for a further exploration of integrated approaches to osteoporosis therapy combining pharmacological treatment and lifestyle adjustments.</p><p>Clearly, the goal of osteoporosis therapy is the reduction of fracture risk during and after therapy. While BMD has a prime role in the evaluation of osteoporosis therapies and can be measured rather easily using dual-energy x-ray absorptiometry (DXA), its relationship to fracture risk is complex. Fracture risk calculations used in clinical practice also involve demographic and lifestyle-related factors while mostly relying on BMD point measurements (<xref ref-type="bibr" rid="bib36">Kanis et al., 2009</xref>). However, the quantitative associations between BMD, age, and fracture risk reported in many studies (<xref ref-type="bibr" rid="bib35">Kanis et al., 2001</xref>; <xref ref-type="bibr" rid="bib5">Berger et al., 2009</xref>; <xref ref-type="bibr" rid="bib2">Austin et al., 2012</xref>; <xref ref-type="bibr" rid="bib41">Krege et al., 2013</xref>; <xref ref-type="bibr" rid="bib8">Black et al., 2018</xref>; <xref ref-type="bibr" rid="bib19">Ensrud et al., 2022</xref>) can be used to create statistical models that may relate entire BMD time courses to a patient’s fracture risk. Combining such statistical models with the physiology-based model presented here would enable to optimize therapies directly for a minimized long-term fracture risk instead of maximized BMD gain. Thus, our model can serve as a quantitative starting point for the forecast of pharmacological therapies of osteoporosis but also highlights the role of mechanistic mathematical descriptions in understanding the biological principles of drug action.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Hybrid aging/treatment datasets</title><p>To create hybrid aging/treatment datasets, we merged a dataset comprising the BMD age dependence from <xref ref-type="bibr" rid="bib52">Looker et al., 1998</xref> with different clinical study datasets containing the BMD response to various medications (<xref ref-type="table" rid="app3table2">Appendix 3—table 2</xref>). The aging dataset from <xref ref-type="bibr" rid="bib52">Looker et al., 1998</xref> consisted of mean total femur BMD measurements in non-Hispanic white, non-Hispanic black, and Mexican American women, reported in 10-year age bins ranging from 20 to 80 years and older. We used bin averages as proxy BMD indicators for the center of the respective age window (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1B</xref>). Rescaling the reported means for the three ethnic groups to their value for the earliest age bin revealed that relative changes in BMD were remarkably consistent among ethnic groups (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1C</xref>) despite differing absolute baselines. Therefore, and since the model only addresses relative BMD changes, we resorted to the dataset with the largest underlying study population for calibration, which was the dataset comprising the non-Hispanic white female study population. Datasets on the response to medications from clinical trials on romosozumab, blosozumab, denosumab, alendronate, and teriparatide consisted of study population averages of total hip BMD and serum concentrations of one or more BTMs (CTX, P1NP, BSAP) during the treatment, and if available, during a follow-up period. Reported study population averages on the respective quantities were digitized directly from the data figures in the corresponding publications (<xref ref-type="table" rid="app3table2">Appendix 3—table 2</xref>).</p><p>To merge aging and treatment datasets, the BMD from treatment datasets was rescaled such that the BMD baseline at treatment start corresponds to the linearly interpolated age-dependent BMD at treatment start. The treatment start was placed at the average age of the study population upon study start (rounded to full years) as reported in the respective publication (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1D</xref>). BTM measurements were normalized to baseline values.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>DJJ is an employee of Fresenius Medical Care Germany. DJJ is an inventor on a patent application named &quot;Virtual Osteoporosis Clinic&quot; (WO 2021/231374 A1). The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf2"><p>DHF is an employee of Fresenius Medical Care Germany. DHF is an inventor on a patent application named &quot;Virtual Osteoporosis Clinic&quot; (WO 2021/231374 A1). The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf3"><p>AC is an employee of the Renal Research Institute, a wholly owned subsidiary of Fresenius Medical Care. AC is an inventor on a patent application named &quot;Virtual Osteoporosis Clinic&quot; (WO 2021/231374 A1). The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf4"><p>DAB reports a grant from NIH, personal fees, stock and stock options from Tricida; personal fees from and stock in Amgen; personal fees from Relypsa/Vifor/Fresenius; personal fees from Sanifit outside the submitted work. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf5"><p>AM is an employee of the Renal Research Institute, a wholly owned subsidiary of Fresenius Medical Care. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf6"><p>JGR is an employee of the Renal Research Institute, a wholly owned subsidiary of Fresenius Medical Care. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf7"><p>PK is an employee of the Renal Research Institute, a wholly owned subsidiary of Fresenius Medical Care. PK holds stock in Fresenius Medical Care. PK is an inventor on a patent application named &quot;Virtual Osteoporosis Clinic&quot; (WO 2021/231374 A1). The author has no other competing interests to declare</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Biological and clinical expertise, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Biological and clinical expertise, Conceptualization, Investigation, Methodology, Visualization, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-76228-transrepform1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="scode1"><label>Source code 1.</label><caption><title>Simulation codes needed to reproduce the results in the paper.</title></caption><media xlink:href="elife-76228-code1-v1.zip" mimetype="application" mime-subtype="zip"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The current manuscript is a computational study, so no data have been generated for this manuscript. Modelling code including the code needed to produce simulation-related figures is part of the Source Code Files. Digitised data from previously published scientific articles are also part of the Source Code Files. All original source publications are specified in Appendix 3 Table 2 of the manuscript. Data were preprocessed as described in the 'Methods' section of the manuscript. Model parameters are also part of the Source Code Files. In addition, they are provided in Appendix 3 Table 4 of the manuscript.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Friederike E Thomasius for insightful discussions and critical comments on the manuscript.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkins</surname><given-names>GJ</given-names></name><name><surname>Rowe</surname><given-names>PS</given-names></name><name><surname>Lim</surname><given-names>HP</given-names></name><name><surname>Welldon</surname><given-names>KJ</given-names></name><name><surname>Ormsby</surname><given-names>R</given-names></name><name><surname>Wijenayaka</surname><given-names>AR</given-names></name><name><surname>Zelenchuk</surname><given-names>L</given-names></name><name><surname>Evdokiou</surname><given-names>A</given-names></name><name><surname>Findlay</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism</article-title><source>Journal of Bone and Mineral Research</source><volume>26</volume><fpage>1425</fpage><lpage>1436</lpage><pub-id pub-id-type="doi">10.1002/jbmr.345</pub-id><pub-id pub-id-type="pmid">21312267</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>YC</given-names></name><name><surname>Vittinghoff</surname><given-names>E</given-names></name><name><surname>Adami</surname><given-names>S</given-names></name><name><surname>Boonen</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>DC</given-names></name><name><surname>Bianchi</surname><given-names>G</given-names></name><name><surname>Bolognese</surname><given-names>MA</given-names></name><name><surname>Christiansen</surname><given-names>C</given-names></name><name><surname>Eastell</surname><given-names>R</given-names></name><name><surname>Grauer</surname><given-names>A</given-names></name><name><surname>Hawkins</surname><given-names>F</given-names></name><name><surname>Kendler</surname><given-names>DL</given-names></name><name><surname>Oliveri</surname><given-names>B</given-names></name><name><surname>McClung</surname><given-names>MR</given-names></name><name><surname>Reid</surname><given-names>IR</given-names></name><name><surname>Siris</surname><given-names>ES</given-names></name><name><surname>Zanchetta</surname><given-names>J</given-names></name><name><surname>Zerbini</surname><given-names>CAF</given-names></name><name><surname>Libanati</surname><given-names>C</given-names></name><name><surname>Cummings</surname><given-names>SR</given-names></name><collab>FREEDOM Trial</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures</article-title><source>Journal of Bone and Mineral Research</source><volume>27</volume><fpage>687</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1002/jbmr.1472</pub-id><pub-id pub-id-type="pmid">22095631</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayati</surname><given-names>BP</given-names></name><name><surname>Edwards</surname><given-names>CM</given-names></name><name><surname>Webb</surname><given-names>GF</given-names></name><name><surname>Wikswo</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease</article-title><source>Biology Direct</source><volume>5</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1186/1745-6150-5-28</pub-id><pub-id pub-id-type="pmid">20406449</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bekker</surname><given-names>PJ</given-names></name><name><surname>Holloway</surname><given-names>DL</given-names></name><name><surname>Rasmussen</surname><given-names>AS</given-names></name><name><surname>Murphy</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>SW</given-names></name><name><surname>Leese</surname><given-names>PT</given-names></name><name><surname>Holmes</surname><given-names>GB</given-names></name><name><surname>Dunstan</surname><given-names>CR</given-names></name><name><surname>DePaoli</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A single-dose placebo-controlled study of AMG 162, A fully human monoclonal antibody to RANKL, in postmenopausal women</article-title><source>Journal of Bone and Mineral Research</source><volume>19</volume><fpage>1059</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1359/JBMR.040305</pub-id><pub-id pub-id-type="pmid">15176987</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>C</given-names></name><name><surname>Langsetmo</surname><given-names>L</given-names></name><name><surname>Joseph</surname><given-names>L</given-names></name><name><surname>Hanley</surname><given-names>DA</given-names></name><name><surname>Davison</surname><given-names>KS</given-names></name><name><surname>Josse</surname><given-names>RG</given-names></name><name><surname>Prior</surname><given-names>JC</given-names></name><name><surname>Kreiger</surname><given-names>N</given-names></name><name><surname>Tenenhouse</surname><given-names>A</given-names></name><name><surname>Goltzman</surname><given-names>D</given-names></name><collab>CaMos Research Group</collab></person-group><year iso-8601-date="2009">2009</year><article-title>Association between change in BMD and fragility fracture in women and men</article-title><source>Journal of Bone and Mineral Research</source><volume>24</volume><fpage>361</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1359/jbmr.081004</pub-id><pub-id pub-id-type="pmid">18847328</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berkhout</surname><given-names>J</given-names></name><name><surname>Stone</surname><given-names>JA</given-names></name><name><surname>Verhamme</surname><given-names>KM</given-names></name><name><surname>Stricker</surname><given-names>BH</given-names></name><name><surname>Sturkenboom</surname><given-names>MC</given-names></name><name><surname>Danhof</surname><given-names>M</given-names></name><name><surname>Post</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Application of a systems pharmacology-based placebo population model to analyze long-term data of postmenopausal osteoporosis</article-title><source>CPT</source><volume>4</volume><fpage>516</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1002/psp4.12006</pub-id><pub-id pub-id-type="pmid">26451331</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>DM</given-names></name><name><surname>Schwartz</surname><given-names>AV</given-names></name><name><surname>Ensrud</surname><given-names>KE</given-names></name><name><surname>Cauley</surname><given-names>JA</given-names></name><name><surname>Levis</surname><given-names>S</given-names></name><name><surname>Quandt</surname><given-names>SA</given-names></name><name><surname>Satterfield</surname><given-names>S</given-names></name><name><surname>Wallace</surname><given-names>RB</given-names></name><name><surname>Bauer</surname><given-names>DC</given-names></name><name><surname>Palermo</surname><given-names>L</given-names></name><name><surname>Wehren</surname><given-names>LE</given-names></name><name><surname>Lombardi</surname><given-names>A</given-names></name><name><surname>Santora</surname><given-names>AC</given-names></name><name><surname>Cummings</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Effects of continuing or stopping alendronate after 5 years of treatment</article-title><source>JAMA</source><volume>296</volume><elocation-id>2927</elocation-id><pub-id pub-id-type="doi">10.1001/jama.296.24.2927</pub-id><pub-id pub-id-type="pmid">17190893</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>DM</given-names></name><name><surname>Cauley</surname><given-names>JA</given-names></name><name><surname>Wagman</surname><given-names>R</given-names></name><name><surname>Ensrud</surname><given-names>K</given-names></name><name><surname>Fink</surname><given-names>HA</given-names></name><name><surname>Hillier</surname><given-names>TA</given-names></name><name><surname>Lui</surname><given-names>LY</given-names></name><name><surname>Cummings</surname><given-names>SR</given-names></name><name><surname>Schousboe</surname><given-names>JT</given-names></name><name><surname>Napoli</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The ability of a single BMD and fracture history assessment to predict fracture over 25 years in postmenopausal women: The study of osteoporotic fractures</article-title><source>Journal of Bone and Mineral Research</source><volume>33</volume><fpage>389</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1002/jbmr.3194</pub-id><pub-id pub-id-type="pmid">28719727</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bone</surname><given-names>HG</given-names></name><name><surname>Bolognese</surname><given-names>MA</given-names></name><name><surname>Yuen</surname><given-names>CK</given-names></name><name><surname>Kendler</surname><given-names>DL</given-names></name><name><surname>Miller</surname><given-names>PD</given-names></name><name><surname>Yang</surname><given-names>YC</given-names></name><name><surname>Grazette</surname><given-names>L</given-names></name><name><surname>San Martin</surname><given-names>J</given-names></name><name><surname>Gallagher</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>96</volume><fpage>972</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1210/jc.2010-1502</pub-id><pub-id pub-id-type="pmid">21289258</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boskey</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Bone composition: relationship to bone fragility and antiosteoporotic drug effects</article-title><source>BoneKEy Reports</source><volume>2</volume><elocation-id>447</elocation-id><pub-id pub-id-type="doi">10.1038/bonekey.2013.181</pub-id><pub-id pub-id-type="pmid">24501681</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyce</surname><given-names>BF</given-names></name><name><surname>Xing</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Functions of RANKL/RANK/OPG in bone modeling and remodeling</article-title><source>Archives of Biochemistry and Biophysics</source><volume>473</volume><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2008.03.018</pub-id><pub-id pub-id-type="pmid">18395508</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buenzli</surname><given-names>PR</given-names></name><name><surname>Pivonka</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Spatio-temporal structure of cell distribution in cortical bone multicellular units: A mathematical model</article-title><source>Bone</source><volume>48</volume><fpage>918</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2010.12.009</pub-id><pub-id pub-id-type="pmid">21172465</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buenzli</surname><given-names>PR</given-names></name><name><surname>Pivonka</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Bone refilling in cortical basic multicellular units: insights into tetracycline double labelling from a computational model</article-title><source>Biomechanics and Modeling in Mechanobiology</source><volume>13</volume><fpage>185</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1007/s10237-013-0495-y</pub-id><pub-id pub-id-type="pmid">23632774</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burge</surname><given-names>R</given-names></name><name><surname>Dawson-Hughes</surname><given-names>B</given-names></name><name><surname>Solomon</surname><given-names>DH</given-names></name><name><surname>Wong</surname><given-names>JB</given-names></name><name><surname>King</surname><given-names>A</given-names></name><name><surname>Tosteson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025</article-title><source>Journal of Bone and Mineral Research</source><volume>22</volume><fpage>465</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1359/jbmr.061113</pub-id><pub-id pub-id-type="pmid">17144789</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Normal bone anatomy and physiology</article-title><source>Clinical Journal of the American Society of Nephrology</source><volume>3</volume><fpage>S131</fpage><lpage>S139</lpage><pub-id pub-id-type="doi">10.2215/CJN.04151206</pub-id><pub-id pub-id-type="pmid">18988698</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><source>IOF Compendium of Osteoporosis</source><publisher-name>International Osteoporosis Foundation</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.osteoporosis.foundation/sites/iofbonehealth/files/2020-01/IOF-Compendium-of-Osteoporosis-web-V02.pdf">https://www.osteoporosis.foundation/sites/iofbonehealth/files/2020-01/IOF-Compendium-of-Osteoporosis-web-V02.pdf</ext-link></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cosman</surname><given-names>F</given-names></name><name><surname>Crittenden</surname><given-names>DB</given-names></name><name><surname>Adachi</surname><given-names>JD</given-names></name><name><surname>Binkley</surname><given-names>N</given-names></name><name><surname>Czerwinski</surname><given-names>E</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Hofbauer</surname><given-names>LC</given-names></name><name><surname>Lau</surname><given-names>E</given-names></name><name><surname>Lewiecki</surname><given-names>EM</given-names></name><name><surname>Miyauchi</surname><given-names>A</given-names></name><name><surname>Zerbini</surname><given-names>CAF</given-names></name><name><surname>Milmont</surname><given-names>CE</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Maddox</surname><given-names>J</given-names></name><name><surname>Meisner</surname><given-names>PD</given-names></name><name><surname>Libanati</surname><given-names>C</given-names></name><name><surname>Grauer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Romosozumab treatment in postmenopausal women with osteoporosis</article-title><source>The New England Journal of Medicine</source><volume>375</volume><fpage>1532</fpage><lpage>1543</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1607948</pub-id><pub-id pub-id-type="pmid">27641143</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delgado-Calle</surname><given-names>J</given-names></name><name><surname>Sato</surname><given-names>AY</given-names></name><name><surname>Bellido</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Role and mechanism of action of sclerostin in bone</article-title><source>Bone</source><volume>96</volume><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2016.10.007</pub-id><pub-id pub-id-type="pmid">27742498</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ensrud</surname><given-names>KE</given-names></name><name><surname>Lui</surname><given-names>LY</given-names></name><name><surname>Crandall</surname><given-names>CJ</given-names></name><name><surname>Orwoll</surname><given-names>ES</given-names></name><name><surname>Langsetmo</surname><given-names>L</given-names></name><name><surname>Schousboe</surname><given-names>JT</given-names></name><name><surname>Fink</surname><given-names>HA</given-names></name><name><surname>Lane</surname><given-names>NE</given-names></name><name><surname>Kado</surname><given-names>DM</given-names></name><name><surname>Cauley</surname><given-names>JA</given-names></name><name><surname>Stefanick</surname><given-names>ML</given-names></name><name><surname>Cawthon</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Repeat bone mineral density screening measurement and fracture prediction in older men: a prospective cohort study</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>19</volume><elocation-id>dgac324</elocation-id><pub-id pub-id-type="doi">10.1210/clinem/dgac324</pub-id><pub-id pub-id-type="pmid">35587517</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksen</surname><given-names>EF</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cellular mechanisms of bone remodeling</article-title><source>Reviews in Endocrine &amp; Metabolic Disorders</source><volume>11</volume><fpage>219</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1007/s11154-010-9153-1</pub-id><pub-id pub-id-type="pmid">21188536</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eudy</surname><given-names>RJ</given-names></name><name><surname>Gastonguay</surname><given-names>MR</given-names></name><name><surname>Baron</surname><given-names>KT</given-names></name><name><surname>Riggs</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Connecting the dots: linking osteocyte activity and therapeutic modulation of sclerostin by extending a multiscale systems model</article-title><source>CPT</source><volume>4</volume><fpage>527</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1002/psp4.12013</pub-id><pub-id pub-id-type="pmid">26451332</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuller</surname><given-names>K</given-names></name><name><surname>Chambers</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Localisation of mRNA for collagenase in osteocytic, bone surface and chondrocytic cells but not osteoclasts</article-title><source>Journal of Cell Science</source><volume>108</volume><fpage>2221</fpage><lpage>2230</lpage><pub-id pub-id-type="doi">10.1242/jcs.108.6.2221</pub-id><pub-id pub-id-type="pmid">7673342</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gazzerro</surname><given-names>E</given-names></name><name><surname>Rydziel</surname><given-names>S</given-names></name><name><surname>Canalis</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Skeletal bone morphogenetic proteins suppress the expression of collagenase-3 by rat osteoblasts</article-title><source>Endocrinology</source><volume>140</volume><fpage>562</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1210/endo.140.2.6493</pub-id><pub-id pub-id-type="pmid">9927278</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>JM</given-names></name><name><surname>Ayati</surname><given-names>BP</given-names></name><name><surname>Holstein</surname><given-names>SA</given-names></name><name><surname>Martin</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The role of osteocytes in targeted bone remodeling: a mathematical model</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e63884</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0063884</pub-id><pub-id pub-id-type="pmid">23717504</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gullberg</surname><given-names>B</given-names></name><name><surname>Johnell</surname><given-names>O</given-names></name><name><surname>Kanis</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>World-wide projections for hip fracture</article-title><source>Osteoporosis International</source><volume>7</volume><fpage>407</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1007/pl00004148</pub-id><pub-id pub-id-type="pmid">9425497</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>N</given-names></name><name><surname>Akimoto</surname><given-names>Y</given-names></name><name><surname>Baudis</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>CMA-ES/Pycma on Github</data-title><version designator="r3.2.2">r3.2.2</version><source>Zenodo</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.2559634">https://doi.org/10.5281/zenodo.2559634</ext-link></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattersley</surname><given-names>G</given-names></name><name><surname>Dean</surname><given-names>T</given-names></name><name><surname>Corbin</surname><given-names>BA</given-names></name><name><surname>Bahar</surname><given-names>H</given-names></name><name><surname>Gardella</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling</article-title><source>Endocrinology</source><volume>157</volume><fpage>141</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1210/en.2015-1726</pub-id><pub-id pub-id-type="pmid">26562265</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernlund</surname><given-names>E</given-names></name><name><surname>Svedbom</surname><given-names>A</given-names></name><name><surname>Ivergård</surname><given-names>M</given-names></name><name><surname>Compston</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Stenmark</surname><given-names>J</given-names></name><name><surname>McCloskey</surname><given-names>EV</given-names></name><name><surname>Jönsson</surname><given-names>B</given-names></name><name><surname>Kanis</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Osteoporosis in the European union: medical management, epidemiology and economic burden</article-title><source>Archives of Osteoporosis</source><volume>8</volume><fpage>1</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1007/s11657-013-0136-1</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hock</surname><given-names>JM</given-names></name><name><surname>Gera</surname><given-names>I</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone</article-title><source>Journal of Bone and Mineral Research</source><volume>7</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1002/jbmr.5650070110</pub-id><pub-id pub-id-type="pmid">1532281</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houde</surname><given-names>N</given-names></name><name><surname>Chamoux</surname><given-names>E</given-names></name><name><surname>Bisson</surname><given-names>M</given-names></name><name><surname>Roux</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim</article-title><source>The Journal of Biological Chemistry</source><volume>284</volume><fpage>23397</fpage><lpage>23404</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.019372</pub-id><pub-id pub-id-type="pmid">19574221</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>DE</given-names></name><name><surname>Dai</surname><given-names>A</given-names></name><name><surname>Tiffee</surname><given-names>JC</given-names></name><name><surname>Li</surname><given-names>HH</given-names></name><name><surname>Mundy</surname><given-names>GR</given-names></name><name><surname>Boyce</surname><given-names>BF</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta</article-title><source>Nature Medicine</source><volume>2</volume><fpage>1132</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1038/nm1096-1132</pub-id><pub-id pub-id-type="pmid">8837613</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name><name><surname>Mitlak</surname><given-names>BH</given-names></name><name><surname>Wang</surname><given-names>O</given-names></name><name><surname>Genant</surname><given-names>HK</given-names></name><name><surname>Eriksen</surname><given-names>EF</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure</article-title><source>Journal of Bone and Mineral Research</source><volume>18</volume><fpage>1932</fpage><lpage>1941</lpage><pub-id pub-id-type="doi">10.1359/jbmr.2003.18.11.1932</pub-id><pub-id pub-id-type="pmid">14606504</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jilka</surname><given-names>RL</given-names></name><name><surname>Weinstein</surname><given-names>RS</given-names></name><name><surname>Bellido</surname><given-names>T</given-names></name><name><surname>Roberson</surname><given-names>P</given-names></name><name><surname>Parfitt</surname><given-names>AM</given-names></name><name><surname>Manolagas</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone</article-title><source>The Journal of Clinical Investigation</source><volume>104</volume><fpage>439</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1172/JCI6610</pub-id><pub-id pub-id-type="pmid">10449436</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kameda</surname><given-names>T</given-names></name><name><surname>Mano</surname><given-names>H</given-names></name><name><surname>Yuasa</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Miyazawa</surname><given-names>K</given-names></name><name><surname>Shiokawa</surname><given-names>M</given-names></name><name><surname>Nakamaru</surname><given-names>Y</given-names></name><name><surname>Hiroi</surname><given-names>E</given-names></name><name><surname>Hiura</surname><given-names>K</given-names></name><name><surname>Kameda</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>NN</given-names></name><name><surname>Hakeda</surname><given-names>Y</given-names></name><name><surname>Kumegawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts</article-title><source>The Journal of Experimental Medicine</source><volume>186</volume><fpage>489</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1084/jem.186.4.489</pub-id><pub-id pub-id-type="pmid">9254647</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanis</surname><given-names>JA</given-names></name><name><surname>Johnell</surname><given-names>O</given-names></name><name><surname>Oden</surname><given-names>A</given-names></name><name><surname>Dawson</surname><given-names>A</given-names></name><name><surname>De Laet</surname><given-names>C</given-names></name><name><surname>Jonsson</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds</article-title><source>Osteoporosis International</source><volume>12</volume><fpage>989</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1007/s001980170006</pub-id><pub-id pub-id-type="pmid">11846333</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanis</surname><given-names>JA</given-names></name><name><surname>Oden</surname><given-names>A</given-names></name><name><surname>Johansson</surname><given-names>H</given-names></name><name><surname>Borgström</surname><given-names>F</given-names></name><name><surname>Ström</surname><given-names>O</given-names></name><name><surname>McCloskey</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>FRAX and its applications to clinical practice</article-title><source>Bone</source><volume>44</volume><fpage>734</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2009.01.373</pub-id><pub-id pub-id-type="pmid">19195497</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Keener</surname><given-names>J</given-names></name><name><surname>Sneyd</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><source>Mathematical Physiology</source><edition>2nd edition</edition><publisher-loc>New York, NY</publisher-loc><publisher-name>Springer-Verlag</publisher-name><pub-id pub-id-type="doi">10.1007/978-0-387-75847-3</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komarova</surname><given-names>SV</given-names></name><name><surname>Smith</surname><given-names>RJ</given-names></name><name><surname>Dixon</surname><given-names>SJ</given-names></name><name><surname>Sims</surname><given-names>SM</given-names></name><name><surname>Wahl</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling</article-title><source>Bone</source><volume>33</volume><fpage>206</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/s8756-3282(03)00157-1</pub-id><pub-id pub-id-type="pmid">14499354</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komarova</surname><given-names>SV</given-names></name><name><surname>Safranek</surname><given-names>L</given-names></name><name><surname>Gopalakrishnan</surname><given-names>J</given-names></name><name><surname>Ou</surname><given-names>MJY</given-names></name><name><surname>McKee</surname><given-names>MD</given-names></name><name><surname>Murshed</surname><given-names>M</given-names></name><name><surname>Rauch</surname><given-names>F</given-names></name><name><surname>Zuhr</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mathematical model for bone mineralization</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>3</volume><elocation-id>51</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2015.00051</pub-id><pub-id pub-id-type="pmid">26347868</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostenuik</surname><given-names>PJ</given-names></name><name><surname>Nguyen</surname><given-names>HQ</given-names></name><name><surname>McCabe</surname><given-names>J</given-names></name><name><surname>Warmington</surname><given-names>KS</given-names></name><name><surname>Kurahara</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Cattley</surname><given-names>RC</given-names></name><name><surname>Van</surname><given-names>G</given-names></name><name><surname>Scully</surname><given-names>S</given-names></name><name><surname>Elliott</surname><given-names>R</given-names></name><name><surname>Grisanti</surname><given-names>M</given-names></name><name><surname>Morony</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>HL</given-names></name><name><surname>Asuncion</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ominsky</surname><given-names>MS</given-names></name><name><surname>Stolina</surname><given-names>M</given-names></name><name><surname>Dwyer</surname><given-names>D</given-names></name><name><surname>Dougall</surname><given-names>WC</given-names></name><name><surname>Hawkins</surname><given-names>N</given-names></name><name><surname>Boyle</surname><given-names>WJ</given-names></name><name><surname>Simonet</surname><given-names>WS</given-names></name><name><surname>Sullivan</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL</article-title><source>Journal of Bone and Mineral Research</source><volume>24</volume><fpage>182</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1359/jbmr.081112</pub-id><pub-id pub-id-type="pmid">19016581</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krege</surname><given-names>JH</given-names></name><name><surname>Wan</surname><given-names>X</given-names></name><name><surname>Lentle</surname><given-names>BC</given-names></name><name><surname>Berger</surname><given-names>C</given-names></name><name><surname>Langsetmo</surname><given-names>L</given-names></name><name><surname>Adachi</surname><given-names>JD</given-names></name><name><surname>Prior</surname><given-names>JC</given-names></name><name><surname>Tenenhouse</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>JP</given-names></name><name><surname>Kreiger</surname><given-names>N</given-names></name><name><surname>Olszynski</surname><given-names>WP</given-names></name><name><surname>Josse</surname><given-names>RG</given-names></name><name><surname>Goltzman</surname><given-names>D</given-names></name><collab>CaMos Research Group</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Fracture risk prediction: importance of age, BMD and spine fracture status</article-title><source>BoneKEy Reports</source><volume>2</volume><elocation-id>404</elocation-id><pub-id pub-id-type="doi">10.1038/bonekey.2013.138</pub-id><pub-id pub-id-type="pmid">24228164</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavaill</surname><given-names>M</given-names></name><name><surname>Trichilo</surname><given-names>S</given-names></name><name><surname>Scheiner</surname><given-names>S</given-names></name><name><surname>Forwood</surname><given-names>MR</given-names></name><name><surname>Cooper</surname><given-names>DML</given-names></name><name><surname>Pivonka</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Study of the combined effects of PTH treatment and mechanical loading in postmenopausal osteoporosis using a new mechanistic PK-PD model</article-title><source>Biomechanics and Modeling in Mechanobiology</source><volume>19</volume><fpage>1765</fpage><lpage>1780</lpage><pub-id pub-id-type="doi">10.1007/s10237-020-01307-6</pub-id><pub-id pub-id-type="pmid">32100180</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leder</surname><given-names>BZ</given-names></name><name><surname>Tsai</surname><given-names>JN</given-names></name><name><surname>Uihlein</surname><given-names>AV</given-names></name><name><surname>Burnett-Bowie</surname><given-names>SAM</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Foley</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Neer</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): A randomized controlled trial</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>99</volume><fpage>1694</fpage><lpage>1700</lpage><pub-id pub-id-type="doi">10.1210/jc.2013-4440</pub-id><pub-id pub-id-type="pmid">24517156</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leder</surname><given-names>BZ</given-names></name><name><surname>Tsai</surname><given-names>JN</given-names></name><name><surname>Uihlein</surname><given-names>AV</given-names></name><name><surname>Wallace</surname><given-names>PM</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Neer</surname><given-names>RM</given-names></name><name><surname>Burnett-Bowie</surname><given-names>SAM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial</article-title><source>Lancet</source><volume>386</volume><fpage>1147</fpage><lpage>1155</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)61120-5</pub-id><pub-id pub-id-type="pmid">26144908</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemaire</surname><given-names>V</given-names></name><name><surname>Tobin</surname><given-names>FL</given-names></name><name><surname>Greller</surname><given-names>LD</given-names></name><name><surname>Cho</surname><given-names>CR</given-names></name><name><surname>Suva</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Modeling the interactions between osteoblast and osteoclast activities in bone remodeling</article-title><source>Journal of Theoretical Biology</source><volume>229</volume><fpage>293</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2004.03.023</pub-id><pub-id pub-id-type="pmid">15234198</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemaire</surname><given-names>V</given-names></name><name><surname>Cox</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dynamics of bone cell interactions and differential responses to PTH and antibody-based therapies</article-title><source>Bulletin of Mathematical Biology</source><volume>81</volume><fpage>3575</fpage><lpage>3622</lpage><pub-id pub-id-type="doi">10.1007/s11538-018-0533-0</pub-id><pub-id pub-id-type="pmid">30460589</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewiecki</surname><given-names>EM</given-names></name><name><surname>Dinavahi</surname><given-names>RV</given-names></name><name><surname>Lazaretti-Castro</surname><given-names>M</given-names></name><name><surname>Ebeling</surname><given-names>PR</given-names></name><name><surname>Adachi</surname><given-names>JD</given-names></name><name><surname>Miyauchi</surname><given-names>A</given-names></name><name><surname>Gielen</surname><given-names>E</given-names></name><name><surname>Milmont</surname><given-names>CE</given-names></name><name><surname>Libanati</surname><given-names>C</given-names></name><name><surname>Grauer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study</article-title><source>Journal of Bone and Mineral Research</source><volume>34</volume><fpage>419</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1002/jbmr.3622</pub-id><pub-id pub-id-type="pmid">30508316</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Harris</surname><given-names>SE</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>19883</fpage><lpage>19887</lpage><pub-id pub-id-type="doi">10.1074/jbc.M413274200</pub-id><pub-id pub-id-type="pmid">15778503</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ominsky</surname><given-names>MS</given-names></name><name><surname>Niu</surname><given-names>QT</given-names></name><name><surname>Sun</surname><given-names>N</given-names></name><name><surname>Daugherty</surname><given-names>B</given-names></name><name><surname>D’Agostin</surname><given-names>D</given-names></name><name><surname>Kurahara</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Asuncion</surname><given-names>F</given-names></name><name><surname>Barrero</surname><given-names>M</given-names></name><name><surname>Warmington</surname><given-names>K</given-names></name><name><surname>Dwyer</surname><given-names>D</given-names></name><name><surname>Stolina</surname><given-names>M</given-names></name><name><surname>Morony</surname><given-names>S</given-names></name><name><surname>Sarosi</surname><given-names>I</given-names></name><name><surname>Kostenuik</surname><given-names>PJ</given-names></name><name><surname>Lacey</surname><given-names>DL</given-names></name><name><surname>Simonet</surname><given-names>WS</given-names></name><name><surname>Ke</surname><given-names>HZ</given-names></name><name><surname>Paszty</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength</article-title><source>Journal of Bone and Mineral Research</source><volume>23</volume><fpage>860</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1359/jbmr.080216</pub-id><pub-id pub-id-type="pmid">18269310</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>SY</given-names></name><name><surname>Bolster</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Profile of romosozumab and its potential in the management of osteoporosis</article-title><source>Drug Design, Development and Therapy</source><volume>11</volume><fpage>1221</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S127568</pub-id><pub-id pub-id-type="pmid">28458516</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lisberg</surname><given-names>A</given-names></name><name><surname>Ellis</surname><given-names>R</given-names></name><name><surname>Nicholson</surname><given-names>K</given-names></name><name><surname>Moku</surname><given-names>P</given-names></name><name><surname>Swarup</surname><given-names>A</given-names></name><name><surname>Dhurjati</surname><given-names>P</given-names></name><name><surname>Nohe</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mathematical modeling of the effects of CK2.3 on mineralization in osteoporotic bone</article-title><source>CPT</source><volume>6</volume><fpage>208</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1002/psp4.12154</pub-id><pub-id pub-id-type="pmid">28181418</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Looker</surname><given-names>AC</given-names></name><name><surname>Wahner</surname><given-names>HW</given-names></name><name><surname>Dunn</surname><given-names>WL</given-names></name><name><surname>Calvo</surname><given-names>MS</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name><name><surname>Heyse</surname><given-names>SP</given-names></name><name><surname>Johnston</surname><given-names>CC</given-names></name><name><surname>Lindsay</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Updated data on proximal femur bone mineral levels of US adults</article-title><source>Osteoporosis International</source><volume>8</volume><fpage>468</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1007/s001980050093</pub-id><pub-id pub-id-type="pmid">9850356</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manolagas</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis</article-title><source>Endocrine Reviews</source><volume>21</volume><fpage>115</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1210/edrv.21.2.0395</pub-id><pub-id pub-id-type="pmid">10782361</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manolagas</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis</article-title><source>Endocrine Reviews</source><volume>31</volume><fpage>266</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1210/er.2009-0024</pub-id><pub-id pub-id-type="pmid">20051526</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marathe</surname><given-names>A</given-names></name><name><surname>Peterson</surname><given-names>MC</given-names></name><name><surname>Mager</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>326</volume><fpage>555</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1124/jpet.108.137703</pub-id><pub-id pub-id-type="pmid">18460643</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marathe</surname><given-names>DD</given-names></name><name><surname>Marathe</surname><given-names>A</given-names></name><name><surname>Mager</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women</article-title><source>Biopharmaceutics &amp; Drug Disposition</source><volume>32</volume><fpage>471</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1002/bdd.770</pub-id><pub-id pub-id-type="pmid">21953540</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maré</surname><given-names>AD</given-names></name><name><surname>D’Haese</surname><given-names>PC</given-names></name><name><surname>Verhulst</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The role of sclerostin in bone and ectopic calcification</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>3199</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21093199</pub-id><pub-id pub-id-type="pmid">32366042</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez-Reina</surname><given-names>J</given-names></name><name><surname>Pivonka</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Effects of long-term treatment of denosumab on bone mineral density: insights from an in-silico model of bone mineralization</article-title><source>Bone</source><volume>125</volume><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2019.04.022</pub-id><pub-id pub-id-type="pmid">31055117</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClung</surname><given-names>MR</given-names></name><name><surname>Lewiecki</surname><given-names>EM</given-names></name><name><surname>Cohen</surname><given-names>SB</given-names></name><name><surname>Bolognese</surname><given-names>MA</given-names></name><name><surname>Woodson</surname><given-names>GC</given-names></name><name><surname>Moffett</surname><given-names>AH</given-names></name><name><surname>Peacock</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>PD</given-names></name><name><surname>Lederman</surname><given-names>SN</given-names></name><name><surname>Chesnut</surname><given-names>CH</given-names></name><name><surname>Lain</surname><given-names>D</given-names></name><name><surname>Kivitz</surname><given-names>AJ</given-names></name><name><surname>Holloway</surname><given-names>DL</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Peterson</surname><given-names>MC</given-names></name><name><surname>Bekker</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Denosumab in postmenopausal women with low Bone mineral density</article-title><source>New England Journal of Medicine</source><volume>354</volume><fpage>821</fpage><lpage>831</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa044459</pub-id><pub-id pub-id-type="pmid">16495394</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClung</surname><given-names>MR</given-names></name><name><surname>Wagman</surname><given-names>RB</given-names></name><name><surname>Miller</surname><given-names>PD</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Lewiecki</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Observations following discontinuation of long-term denosumab therapy</article-title><source>Osteoporosis International</source><volume>28</volume><fpage>1723</fpage><lpage>1732</lpage><pub-id pub-id-type="doi">10.1007/s00198-017-3919-1</pub-id><pub-id pub-id-type="pmid">28144701</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClung</surname><given-names>MR</given-names></name><name><surname>Brown</surname><given-names>JP</given-names></name><name><surname>Diez-Perez</surname><given-names>A</given-names></name><name><surname>Resch</surname><given-names>H</given-names></name><name><surname>Caminis</surname><given-names>J</given-names></name><name><surname>Meisner</surname><given-names>P</given-names></name><name><surname>Bolognese</surname><given-names>MA</given-names></name><name><surname>Goemaere</surname><given-names>S</given-names></name><name><surname>Bone</surname><given-names>HG</given-names></name><name><surname>Zanchetta</surname><given-names>JR</given-names></name><name><surname>Maddox</surname><given-names>J</given-names></name><name><surname>Bray</surname><given-names>S</given-names></name><name><surname>Grauer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women With low bone mineral density: a randomized, double-blind, phase 2, parallel group study</article-title><source>Journal of Bone and Mineral Research</source><volume>33</volume><fpage>1397</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1002/jbmr.3452</pub-id><pub-id pub-id-type="pmid">29694685</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mödder</surname><given-names>UIL</given-names></name><name><surname>Clowes</surname><given-names>JA</given-names></name><name><surname>Hoey</surname><given-names>K</given-names></name><name><surname>Peterson</surname><given-names>JM</given-names></name><name><surname>McCready</surname><given-names>L</given-names></name><name><surname>Oursler</surname><given-names>MJ</given-names></name><name><surname>Riggs</surname><given-names>BL</given-names></name><name><surname>Khosla</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Regulation of circulating sclerostin levels by sex steroids in women and in men</article-title><source>Journal of Bone and Mineral Research</source><volume>26</volume><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1002/jbmr.128</pub-id><pub-id pub-id-type="pmid">20499362</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mundy</surname><given-names>GR</given-names></name><name><surname>Guise</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Hormonal control of calcium homeostasis</article-title><source>Clinical Chemistry</source><volume>45</volume><fpage>1347</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.1093/clinchem/45.8.1347</pub-id><pub-id pub-id-type="pmid">10430817</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odén</surname><given-names>A</given-names></name><name><surname>McCloskey</surname><given-names>EV</given-names></name><name><surname>Johansson</surname><given-names>H</given-names></name><name><surname>Kanis</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Assessing the impact of osteoporosis on the burden of hip fractures</article-title><source>Calcified Tissue International</source><volume>92</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1007/s00223-012-9666-6</pub-id><pub-id pub-id-type="pmid">23135744</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Oliphant</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2006">2006</year><source>A Guide to NumPy</source><publisher-name>Trelgol Publishing USA</publisher-name></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ominsky</surname><given-names>MS</given-names></name><name><surname>Vlasseros</surname><given-names>F</given-names></name><name><surname>Jolette</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>SY</given-names></name><name><surname>Stouch</surname><given-names>B</given-names></name><name><surname>Doellgast</surname><given-names>G</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Graham</surname><given-names>K</given-names></name><name><surname>Tipton</surname><given-names>B</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Deshpande</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Hale</surname><given-names>MD</given-names></name><name><surname>Lightwood</surname><given-names>DJ</given-names></name><name><surname>Henry</surname><given-names>AJ</given-names></name><name><surname>Popplewell</surname><given-names>AG</given-names></name><name><surname>Moore</surname><given-names>AR</given-names></name><name><surname>Robinson</surname><given-names>MK</given-names></name><name><surname>Lacey</surname><given-names>DL</given-names></name><name><surname>Simonet</surname><given-names>WS</given-names></name><name><surname>Paszty</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation</article-title><source>Bone Mineral Density, and Bone Strength. J. Bone Miner. Res</source><volume>25</volume><fpage>948</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1002/jbmr.14</pub-id><pub-id pub-id-type="pmid">20200929</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Painter</surname><given-names>SE</given-names></name><name><surname>Kleerekoper</surname><given-names>M</given-names></name><name><surname>Camacho</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Secondary osteoporosis: a review of the recent evidence</article-title><source>Endocrine Practice</source><volume>12</volume><fpage>436</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.4158/EP.12.4.436</pub-id><pub-id pub-id-type="pmid">16901802</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>MC</given-names></name><name><surname>Riggs</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling</article-title><source>Bone</source><volume>46</volume><fpage>49</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2009.08.053</pub-id><pub-id pub-id-type="pmid">19732857</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pivonka</surname><given-names>P</given-names></name><name><surname>Zimak</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>DW</given-names></name><name><surname>Gardiner</surname><given-names>BS</given-names></name><name><surname>Dunstan</surname><given-names>CR</given-names></name><name><surname>Sims</surname><given-names>NA</given-names></name><name><surname>John Martin</surname><given-names>T</given-names></name><name><surname>Mundy</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Model structure and control of bone remodeling: a theoretical study</article-title><source>Bone</source><volume>43</volume><fpage>249</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2008.03.025</pub-id><pub-id pub-id-type="pmid">18514606</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pivonka</surname><given-names>P</given-names></name><name><surname>Zimak</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>DW</given-names></name><name><surname>Gardiner</surname><given-names>BS</given-names></name><name><surname>Dunstan</surname><given-names>CR</given-names></name><name><surname>Sims</surname><given-names>NA</given-names></name><name><surname>Martin</surname><given-names>TJ</given-names></name><name><surname>Mundy</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling</article-title><source>Journal of Theoretical Biology</source><volume>262</volume><fpage>306</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2009.09.021</pub-id><pub-id pub-id-type="pmid">19782692</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pivonka</surname><given-names>P.</given-names></name><name><surname>Buenzli</surname><given-names>PR</given-names></name><name><surname>Scheiner</surname><given-names>S</given-names></name><name><surname>Hellmich</surname><given-names>C</given-names></name><name><surname>Dunstan</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The influence of bone surface availability in bone remodelling—A mathematical model including coupled geometrical and biomechanical regulations of bone cells</article-title><source>Engineering Structures</source><volume>47</volume><fpage>134</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.engstruct.2012.09.006</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Recknor</surname><given-names>CP</given-names></name><name><surname>Recker</surname><given-names>RR</given-names></name><name><surname>Benson</surname><given-names>CT</given-names></name><name><surname>Robins</surname><given-names>DA</given-names></name><name><surname>Chiang</surname><given-names>AY</given-names></name><name><surname>Alam</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Sowa</surname><given-names>H</given-names></name><name><surname>Sloan</surname><given-names>JH</given-names></name><name><surname>Konrad</surname><given-names>RJ</given-names></name><name><surname>Mitlak</surname><given-names>BH</given-names></name><name><surname>Sipos</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density</article-title><source>Journal of Bone and Mineral Research</source><volume>30</volume><fpage>1717</fpage><lpage>1725</lpage><pub-id pub-id-type="doi">10.1002/jbmr.2489</pub-id><pub-id pub-id-type="pmid">25707611</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riggs</surname><given-names>BL</given-names></name><name><surname>Khosla</surname><given-names>S</given-names></name><name><surname>Melton</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men</article-title><source>Journal of Bone and Mineral Research</source><volume>13</volume><fpage>763</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1359/jbmr.1998.13.5.763</pub-id><pub-id pub-id-type="pmid">9610739</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodan</surname><given-names>GA</given-names></name><name><surname>Fleisch</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Bisphosphonates: mechanisms of action</article-title><source>The Journal of Clinical Investigation</source><volume>97</volume><fpage>2692</fpage><lpage>2696</lpage><pub-id pub-id-type="doi">10.1172/JCI118722</pub-id><pub-id pub-id-type="pmid">8675678</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>DS</given-names></name><name><surname>Battista</surname><given-names>C</given-names></name><name><surname>Cabal</surname><given-names>A</given-names></name><name><surname>Mehta</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Dynamics of bone cell signaling and PTH treatments of osteoporosis</article-title><source>Discrete and Continuous Dynamical Systems - Series B</source><volume>17</volume><fpage>2185</fpage><lpage>2200</lpage><pub-id pub-id-type="doi">10.3934/dcdsb.2012.17.2185</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rydziel</surname><given-names>S</given-names></name><name><surname>Delany</surname><given-names>AM</given-names></name><name><surname>Canalis</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1997">1997a</year><article-title>Insulin-like growth factor I inhibits the transcription of collagenase 3 in osteoblast cultures</article-title><source>Journal of Cellular Biochemistry</source><volume>67</volume><fpage>176</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-4644(19971101)67:2&lt;176::AID-JCB3&gt;3.0.CO;2-U</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rydziel</surname><given-names>S</given-names></name><name><surname>Varghese</surname><given-names>S</given-names></name><name><surname>Canalis</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1997">1997b</year><article-title>Transforming growth factor β1 inhibits collagenase 3 expression by transcriptional and post-transcriptional mechanisms in osteoblast cultures</article-title><source>Journal of Cellular Physiology</source><volume>170</volume><fpage>145</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-4652(199702)170:2&lt;145::AID-JCP6&gt;3.0.CO;2-O</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryser</surname><given-names>MD</given-names></name><name><surname>Nigam</surname><given-names>N</given-names></name><name><surname>Komarova</surname><given-names>SV</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mathematical modeling of spatio-temporal dynamics of a single bone multicellular unit</article-title><source>Journal of Bone and Mineral Research</source><volume>24</volume><fpage>860</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1359/jbmr.081229</pub-id><pub-id pub-id-type="pmid">19063683</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saag</surname><given-names>KG</given-names></name><name><surname>Petersen</surname><given-names>J</given-names></name><name><surname>Brandi</surname><given-names>ML</given-names></name><name><surname>Karaplis</surname><given-names>AC</given-names></name><name><surname>Lorentzon</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>T</given-names></name><name><surname>Maddox</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>M</given-names></name><name><surname>Meisner</surname><given-names>PD</given-names></name><name><surname>Grauer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Romosozumab or alendronate for fracture prevention in women with osteoporosis</article-title><source>New England Journal of Medicine</source><volume>377</volume><fpage>1417</fpage><lpage>1427</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1708322</pub-id><pub-id pub-id-type="pmid">28892457</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Grasser</surname><given-names>W</given-names></name><name><surname>Endo</surname><given-names>N</given-names></name><name><surname>Akins</surname><given-names>R</given-names></name><name><surname>Simmons</surname><given-names>H</given-names></name><name><surname>Thompson</surname><given-names>DD</given-names></name><name><surname>Golub</surname><given-names>E</given-names></name><name><surname>Rodan</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure</article-title><source>Journal of Clinical Investigation</source><volume>88</volume><fpage>2095</fpage><lpage>2105</lpage><pub-id pub-id-type="doi">10.1172/JCI115539</pub-id><pub-id pub-id-type="pmid">1661297</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satterwhite</surname><given-names>J</given-names></name><name><surname>Heathman</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>PD</given-names></name><name><surname>Marín</surname><given-names>F</given-names></name><name><surname>Glass</surname><given-names>EV</given-names></name><name><surname>Dobnig</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis</article-title><source>Calcified Tissue International</source><volume>87</volume><fpage>485</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1007/s00223-010-9424-6</pub-id><pub-id pub-id-type="pmid">20953593</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheiner</surname><given-names>S</given-names></name><name><surname>Pivonka</surname><given-names>P</given-names></name><name><surname>Hellmich</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Coupling systems biology with multiscale mechanics, for computer simulations of bone remodeling</article-title><source>Computer Methods in Applied Mechanics and Engineering</source><volume>254</volume><fpage>181</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.cma.2012.10.015</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheiner</surname><given-names>S</given-names></name><name><surname>Pivonka</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>DW</given-names></name><name><surname>Dunstan</surname><given-names>CR</given-names></name><name><surname>Hellmich</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab</article-title><source>International Journal for Numerical Methods in Biomedical Engineering</source><volume>30</volume><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1002/cnm.2584</pub-id><pub-id pub-id-type="pmid">24039120</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Post</surname><given-names>TM</given-names></name><name><surname>Peletier</surname><given-names>LA</given-names></name><name><surname>Boroujerdi</surname><given-names>MA</given-names></name><name><surname>Danhof</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Coping with time scales in disease systems analysis: application to bone remodeling</article-title><source>Journal of Pharmacokinetics and Pharmacodynamics</source><volume>38</volume><fpage>873</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1007/s10928-011-9224-2</pub-id><pub-id pub-id-type="pmid">22028207</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>JA</given-names></name><name><surname>Partridge</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Physiological bone remodeling: systemic regulation and growth factor involvement</article-title><source>Physiology</source><volume>31</volume><fpage>233</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1152/physiol.00061.2014</pub-id><pub-id pub-id-type="pmid">27053737</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solheim</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Growth factors in bone</article-title><source>International Orthopaedics</source><volume>22</volume><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1007/s002640050290</pub-id><pub-id pub-id-type="pmid">10093814</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solling</surname><given-names>ASK</given-names></name><name><surname>Harsløf</surname><given-names>T</given-names></name><name><surname>Langdahl</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis</article-title><source>Therapeutic Advances in Musculoskeletal Disease</source><volume>10</volume><fpage>105</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1177/1759720X18775936</pub-id><pub-id pub-id-type="pmid">29942362</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowers</surname><given-names>MR</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>McConnell</surname><given-names>D</given-names></name><name><surname>Nan</surname><given-names>B</given-names></name><name><surname>Harlow</surname><given-names>SD</given-names></name><name><surname>Randolph</surname><given-names>JF</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2008">2008</year><article-title>Estradiol rates of change in relation to the final menstrual period in a population-based cohort of women</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>93</volume><fpage>3847</fpage><lpage>3852</lpage><pub-id pub-id-type="doi">10.1210/jc.2008-1056</pub-id><pub-id pub-id-type="pmid">18647803</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streicher</surname><given-names>C</given-names></name><name><surname>Heyny</surname><given-names>A</given-names></name><name><surname>Andrukhova</surname><given-names>O</given-names></name><name><surname>Haigl</surname><given-names>B</given-names></name><name><surname>Slavic</surname><given-names>S</given-names></name><name><surname>Schüler</surname><given-names>C</given-names></name><name><surname>Kollmann</surname><given-names>K</given-names></name><name><surname>Kantner</surname><given-names>I</given-names></name><name><surname>Sexl</surname><given-names>V</given-names></name><name><surname>Kleiter</surname><given-names>M</given-names></name><name><surname>Hofbauer</surname><given-names>LC</given-names></name><name><surname>Kostenuik</surname><given-names>PJ</given-names></name><name><surname>Erben</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Estrogen regulates bone turnover by targeting RANKL expression in bone lining cells</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>6460</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-06614-0</pub-id><pub-id pub-id-type="pmid">28744019</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suen</surname><given-names>PK</given-names></name><name><surname>Zhu</surname><given-names>TY</given-names></name><name><surname>Chow</surname><given-names>DHK</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>LZ</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Sclerostin antibody treatment increases bone formation, bone mass, and bone strength of intact bones in adult male rats</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>15632</elocation-id><pub-id pub-id-type="doi">10.1038/srep15632</pub-id><pub-id pub-id-type="pmid">26494536</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tam</surname><given-names>CS</given-names></name><name><surname>Heersche</surname><given-names>JNM</given-names></name><name><surname>Murray</surname><given-names>TM</given-names></name><name><surname>Parsons</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration</article-title><source>Endocrinology</source><volume>110</volume><fpage>506</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1210/endo-110-2-506</pub-id><pub-id pub-id-type="pmid">7056211</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Adachi</surname><given-names>T</given-names></name><name><surname>Kuroda</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Shiraki</surname><given-names>M</given-names></name><name><surname>Sugimoto</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Bilezikian</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide</article-title><source>Bone Research</source><volume>2</volume><elocation-id>14043</elocation-id><pub-id pub-id-type="doi">10.1038/boneres.2014.43</pub-id><pub-id pub-id-type="pmid">26273530</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thouverey</surname><given-names>C</given-names></name><name><surname>Caverzasio</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro</article-title><source>BoneKEy Reports</source><volume>4</volume><elocation-id>757</elocation-id><pub-id pub-id-type="doi">10.1038/bonekey.2015.126</pub-id><pub-id pub-id-type="pmid">26587226</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>KN</given-names></name><name><surname>Lie</surname><given-names>JD</given-names></name><name><surname>Wan</surname><given-names>CKV</given-names></name><name><surname>Cameron</surname><given-names>M</given-names></name><name><surname>Austel</surname><given-names>AG</given-names></name><name><surname>Nguyen</surname><given-names>JK</given-names></name><name><surname>Van</surname><given-names>K</given-names></name><name><surname>Hyun</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Osteoporosis: a review of treatment options</article-title><source>Pharm. Ther</source><volume>43</volume><fpage>92</fpage><lpage>104</lpage></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virtanen</surname><given-names>P</given-names></name><name><surname>Gommers</surname><given-names>R</given-names></name><name><surname>Oliphant</surname><given-names>TE</given-names></name><name><surname>Haberland</surname><given-names>M</given-names></name><name><surname>Reddy</surname><given-names>T</given-names></name><name><surname>Cournapeau</surname><given-names>D</given-names></name><name><surname>Burovski</surname><given-names>E</given-names></name><name><surname>Peterson</surname><given-names>P</given-names></name><name><surname>Weckesser</surname><given-names>W</given-names></name><name><surname>Bright</surname><given-names>J</given-names></name><name><surname>van der Walt</surname><given-names>SJ</given-names></name><name><surname>Brett</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>J</given-names></name><name><surname>Millman</surname><given-names>KJ</given-names></name><name><surname>Mayorov</surname><given-names>N</given-names></name><name><surname>Nelson</surname><given-names>ARJ</given-names></name><name><surname>Jones</surname><given-names>E</given-names></name><name><surname>Kern</surname><given-names>R</given-names></name><name><surname>Larson</surname><given-names>E</given-names></name><name><surname>Carey</surname><given-names>CJ</given-names></name><name><surname>Polat</surname><given-names>İ</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Moore</surname><given-names>EW</given-names></name><name><surname>VanderPlas</surname><given-names>J</given-names></name><name><surname>Laxalde</surname><given-names>D</given-names></name><name><surname>Perktold</surname><given-names>J</given-names></name><name><surname>Cimrman</surname><given-names>R</given-names></name><name><surname>Henriksen</surname><given-names>I</given-names></name><name><surname>Quintero</surname><given-names>EA</given-names></name><name><surname>Harris</surname><given-names>CR</given-names></name><name><surname>Archibald</surname><given-names>AM</given-names></name><name><surname>Ribeiro</surname><given-names>AH</given-names></name><name><surname>Pedregosa</surname><given-names>F</given-names></name><name><surname>van Mulbregt</surname><given-names>P</given-names></name><collab>SciPy 1.0 Contributors</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Author Correction: SciPy 1.0: fundamental algorithms for scientific computing in Python</article-title><source>Nature Methods</source><volume>17</volume><elocation-id>352</elocation-id><pub-id pub-id-type="doi">10.1038/s41592-020-0772-5</pub-id><pub-id pub-id-type="pmid">32094914</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstein</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Glucocorticoid-induced osteoporosis and osteonecrosis</article-title><source>Endocrinology and Metabolism Clinics of North America</source><volume>41</volume><fpage>595</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1016/j.ecl.2012.04.004</pub-id><pub-id pub-id-type="pmid">22877431</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wijenayaka</surname><given-names>AR</given-names></name><name><surname>Kogawa</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>HP</given-names></name><name><surname>Bonewald</surname><given-names>LF</given-names></name><name><surname>Findlay</surname><given-names>DM</given-names></name><name><surname>Atkins</surname><given-names>GJ</given-names></name><name><surname>Carvalho</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway</article-title><source>PLOS ONE</source><volume>6</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0025900</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>DG</given-names></name><name><surname>Sutherland</surname><given-names>MSK</given-names></name><name><surname>Ojala</surname><given-names>E</given-names></name><name><surname>Turcott</surname><given-names>E</given-names></name><name><surname>Geoghegan</surname><given-names>JC</given-names></name><name><surname>Shpektor</surname><given-names>D</given-names></name><name><surname>Skonier</surname><given-names>JE</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Latham</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>2498</fpage><lpage>2502</lpage><pub-id pub-id-type="doi">10.1074/jbc.M400524200</pub-id><pub-id pub-id-type="pmid">15545262</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Mager</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Systems modeling of bortezomib and dexamethasone combinatorial effects on bone homeostasis in multiple myeloma patients</article-title><source>Journal of Pharmaceutical Sciences</source><volume>108</volume><fpage>732</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2018.11.024</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumsande</surname><given-names>M</given-names></name><name><surname>Stiefs</surname><given-names>D</given-names></name><name><surname>Siegmund</surname><given-names>S</given-names></name><name><surname>Gross</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>General analysis of mathematical models for bone remodeling</article-title><source>Bone</source><volume>48</volume><fpage>910</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2010.12.010</pub-id><pub-id pub-id-type="pmid">21185412</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Model of long-term bone remodeling and osteoporosis</title><p>The model of bone remodeling underlying the present description of osteoporosis and its treatment was built with the aim to provide a minimal set of dynamic components necessary to quantitatively capture population averages of both aging-related changes in bone turnover and the response to osteoporosis medications with different mechanisms of action. The model is partitioned into a core model describing the patient physiology (<xref ref-type="table" rid="app3table1">Appendix 3—table 1</xref>) and separate extensions for different drug classes (<xref ref-type="table" rid="app3table2">Appendix 3—table 2</xref>).</p><p>The model is compartment-based and describes average cell densities, bone densities, and average concentrations of signaling factors within a ‘representative bone remodeling unit (BRU)’, that is, a fictitious BRU corresponding to an average over the considered bone type. All model variables are treated as nondimensional quantities, that is, the model only addresses relative changes in all variables, which simplifies the model structure and reduces the number of free parameters.</p></sec><sec sec-type="appendix" id="s9"><title>Model description</title><p>The model describes the dynamics of the cell densities of pre-osteoclasts (<inline-formula><mml:math id="inf16"><mml:msub><mml:mi>ρ</mml:mi><mml:msup><mml:mi mathvariant="normal">C</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:msub></mml:math></inline-formula>), pre-osteoblasts (<inline-formula><mml:math id="inf17"><mml:msub><mml:mi>ρ</mml:mi><mml:msup><mml:mi mathvariant="normal">B</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:msub></mml:math></inline-formula>), osteoclasts (<inline-formula><mml:math id="inf18"><mml:msub><mml:mi>ρ</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub></mml:math></inline-formula>), osteoblasts (<inline-formula><mml:math id="inf19"><mml:msub><mml:mi>ρ</mml:mi><mml:mi mathvariant="normal">B</mml:mi></mml:msub></mml:math></inline-formula>), osteocytes (<inline-formula><mml:math id="inf20"><mml:msub><mml:mi>ρ</mml:mi><mml:mi mathvariant="normal">Y</mml:mi></mml:msub></mml:math></inline-formula>), as well as functional sclerostin levels (<inline-formula><mml:math id="inf21"><mml:mi>s</mml:mi></mml:math></inline-formula>), total bone density (<inline-formula><mml:math id="inf22"><mml:msub><mml:mi>ρ</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:msub></mml:math></inline-formula>), and BMC (<inline-formula><mml:math id="inf23"><mml:msub><mml:mi>c</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:msub></mml:math></inline-formula>). Functional estrogen levels (<inline-formula><mml:math id="inf24"><mml:mi>e</mml:mi></mml:math></inline-formula>) are provided as an explicitly age-dependent function, described further below. Moreover, the model includes a ‘resorption signal’ (<inline-formula><mml:math id="inf25"><mml:mi>r</mml:mi></mml:math></inline-formula>) corresponding to the composite concentration of bone matrix-derived signaling factors (TGFβ, BMPs, PDGF, IGFs, and FGFs) released upon bone resorption. Sclerostin, estrogen, and the resorption signal act as regulatory factors that modulate the rates of cell proliferation, differentiation, and apoptosis, as well as their bone-forming and -resorbing activity; for notational convenience, they are summarized in the vector <inline-formula><mml:math id="inf26"><mml:mrow><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>e</mml:mi><mml:mo>,</mml:mo><mml:mi>r</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>. Rates that depend on <inline-formula><mml:math id="inf27"><mml:mi mathvariant="bold-italic">ϕ</mml:mi></mml:math></inline-formula> are denoted with a tilde.</p><p>The dynamics of the cell density variables is given by<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mtable columnspacing="5pt" displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:msub><mml:mover accent="true"><mml:mi>ρ</mml:mi><mml:mo>˙</mml:mo></mml:mover><mml:msup><mml:mi mathvariant="normal">C</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:msub></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow><mml:mi/><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>μ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:msup><mml:mi mathvariant="normal">C</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:msup><mml:mi mathvariant="normal">C</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>→</mml:mo><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>η</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:msup><mml:mi mathvariant="normal">C</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mpadded width="+5pt"><mml:msub><mml:mi>ρ</mml:mi><mml:msup><mml:mi mathvariant="normal">C</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:msub></mml:mpadded></mml:mrow></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><disp-formula id="equ2"><label>(2)</label><mml:math id="m2"><mml:mtable columnspacing="5pt" displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:msub><mml:mover accent="true"><mml:mi>ρ</mml:mi><mml:mo>˙</mml:mo></mml:mover><mml:msup><mml:mi mathvariant="normal">B</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:msub></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow><mml:mi/><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>μ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:msup><mml:mi mathvariant="normal">B</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:msup><mml:mi mathvariant="normal">B</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>→</mml:mo><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>η</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:msup><mml:mi mathvariant="normal">B</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mpadded width="+5pt"><mml:msub><mml:mi>ρ</mml:mi><mml:msup><mml:mi mathvariant="normal">B</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:msub></mml:mpadded></mml:mrow></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><disp-formula id="equ3"><label>(3)</label><mml:math id="m3"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mover><mml:mi>ρ</mml:mi><mml:mo>˙</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mo>=</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">→</mml:mo><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>η</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ4"><label>(4)</label><mml:math id="m4"><mml:mtable columnspacing="5pt" displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:msub><mml:mover accent="true"><mml:mi>ρ</mml:mi><mml:mo>˙</mml:mo></mml:mover><mml:mi mathvariant="normal">B</mml:mi></mml:msub></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow><mml:mi/><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:msup><mml:mi mathvariant="normal">B</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>→</mml:mo><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>η</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mi mathvariant="normal">B</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mi mathvariant="normal">B</mml:mi></mml:msub></mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mo>→</mml:mo><mml:mi mathvariant="normal">Y</mml:mi></mml:mrow></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo rspace="7.5pt" stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><disp-formula id="equ5"><label>(5)</label><mml:math id="m5"><mml:mrow><mml:mtable columnalign="right left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mover><mml:mi>ρ</mml:mi><mml:mo>˙</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Y</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mo stretchy="false">→</mml:mo><mml:mrow><mml:mi mathvariant="normal">Y</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>η</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Y</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Y</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>where dots denote time derivatives, <inline-formula><mml:math id="inf28"><mml:msub><mml:mover accent="true"><mml:mi>μ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mi>x</mml:mi></mml:msub></mml:math></inline-formula> denotes the formation rate of cell population <inline-formula><mml:math id="inf29"><mml:mi>x</mml:mi></mml:math></inline-formula>, and <inline-formula><mml:math id="inf30"><mml:msub><mml:mover accent="true"><mml:mi>η</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mi>x</mml:mi></mml:msub></mml:math></inline-formula> denotes its apoptosis rate. Differentiation or conversion from one cell type to another is described by the absolute differentiation rates <inline-formula><mml:math id="inf31"><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>x</mml:mi><mml:mo>→</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> of cell population <inline-formula><mml:math id="inf32"><mml:mi>x</mml:mi></mml:math></inline-formula> giving rise to cells of type <inline-formula><mml:math id="inf33"><mml:mi>y</mml:mi></mml:math></inline-formula>; they have the generic form <inline-formula><mml:math id="inf34"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>x</mml:mi><mml:mo>→</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>ω</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mi>x</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mpadded width="+5pt"><mml:msub><mml:mi>ρ</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:mpadded></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> with <inline-formula><mml:math id="inf35"><mml:msub><mml:mover accent="true"><mml:mi>ω</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mi>x</mml:mi></mml:msub></mml:math></inline-formula> denoting the differentiation rate. All rates are functions of the regulatory factors <inline-formula><mml:math id="inf36"><mml:mi mathvariant="bold-italic">ϕ</mml:mi></mml:math></inline-formula> as indicated.</p><p>Sclerostin is synthesized by osteocytes; the dynamics of Sclerostin levels is given by<disp-formula id="equ6"><label>(6)</label><mml:math id="m6"><mml:mover accent="true"><mml:mi>s</mml:mi><mml:mo>˙</mml:mo></mml:mover><mml:mrow><mml:mrow><mml:mi/><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>α</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mi mathvariant="normal">s</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mi mathvariant="normal">Y</mml:mi></mml:msub></mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>κ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mi mathvariant="normal">s</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mpadded width="+5pt"><mml:mi>s</mml:mi></mml:mpadded></mml:mrow></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf37"><mml:msub><mml:mover accent="true"><mml:mi>α</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mi mathvariant="normal">s</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf38"><mml:msub><mml:mover accent="true"><mml:mi>κ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mi mathvariant="normal">s</mml:mi></mml:msub></mml:math></inline-formula> denote the synthesis and degradation rate, respectively.</p><p>The dynamics of the total bone density (BD) follows:<disp-formula id="equ7"><label>(7)</label><mml:math id="m7"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mrow><mml:mover><mml:mi>ρ</mml:mi><mml:mo>˙</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:msup><mml:mi>b</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msup><mml:mi>b</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msup><mml:mtext> </mml:mtext><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msup><mml:mi>b</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>λ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msup><mml:mi>b</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msup></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>λ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf39"><mml:msup><mml:mi>b</mml:mi><mml:mo>+</mml:mo></mml:msup></mml:math></inline-formula> and <inline-formula><mml:math id="inf40"><mml:msup><mml:mi>b</mml:mi><mml:mo>-</mml:mo></mml:msup></mml:math></inline-formula> are the absolute rates of bone formation and resorption, respectively, with <inline-formula><mml:math id="inf41"><mml:msub><mml:mover accent="true"><mml:mi>λ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mi mathvariant="normal">B</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf42"><mml:msub><mml:mover accent="true"><mml:mi>λ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mi mathvariant="normal">C</mml:mi></mml:msub></mml:math></inline-formula> being the formation and resorption rates per unit osteoblast and osteoclast density, respectively.</p><p>The BMC follows the dynamics<disp-formula id="equ8"><label>(8)</label><mml:math id="m8"><mml:msub><mml:mover accent="true"><mml:mi>c</mml:mi><mml:mo>˙</mml:mo></mml:mover><mml:mi mathvariant="normal">b</mml:mi></mml:msub><mml:mrow><mml:mrow><mml:mi/><mml:mo>=</mml:mo><mml:mrow><mml:mover accent="true"><mml:mi>γ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>c</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mn>0</mml:mn></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:msub></mml:mrow><mml:mo rspace="7.5pt" stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf43"><mml:msub><mml:mover accent="true"><mml:mi>c</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mn>0</mml:mn></mml:msub></mml:math></inline-formula> is the steady-state homeostatic BMC, and <inline-formula><mml:math id="inf44"><mml:mover accent="true"><mml:mi>γ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:math></inline-formula> is the equilibration rate.</p><p>Based on the physiological foundations summarized in the Section 'Mechanisms of bone turnover and its regulation' in the main text, we now specify the functional form of all rates. Upregulation and downregulation through a regulatory factor with concentration <inline-formula><mml:math id="inf45"><mml:mi>x</mml:mi></mml:math></inline-formula> are described by a multiplicative or additive contribution <inline-formula><mml:math id="inf46"><mml:mrow><mml:msup><mml:mi>g</mml:mi><mml:mo>+</mml:mo></mml:msup><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>x</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> or <inline-formula><mml:math id="inf47"><mml:mrow><mml:msup><mml:mi>g</mml:mi><mml:mo>-</mml:mo></mml:msup><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>x</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, respectively, where <italic>x</italic><sub>0</sub> is the threshold concentration at which half-effect is reached (EC<sub>50</sub>) and where <inline-formula><mml:math id="inf48"><mml:msup><mml:mi>g</mml:mi><mml:mo>±</mml:mo></mml:msup></mml:math></inline-formula> are monotonic, saturating functions of the Hill-type (<xref ref-type="bibr" rid="bib37">Keener and Sneyd, 2009</xref>),<disp-formula id="equ9"><mml:math id="m9"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>u</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mi>u</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:mfrac><mml:mtext> </mml:mtext><mml:mo>,</mml:mo><mml:mspace width="2em"/><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>u</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:mfrac><mml:mtext> </mml:mtext><mml:mo>,</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>Using these conventions, the dependencies of rates on regulatory factors are given by<disp-formula id="equ10"><label>(9)</label><mml:math id="m10"><mml:mrow><mml:mtable columnalign="right left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mover><mml:mi>μ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mtext> </mml:mtext><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:msub><mml:mrow><mml:mover><mml:mi>μ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mtext> </mml:mtext><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ11"><label>(10)</label><mml:math id="m11"><mml:mrow><mml:mtable columnalign="right left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mrow><mml:mo fence="true" stretchy="true" symmetric="true" maxsize="2.047em" minsize="2.047em"/></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mover><mml:mi>ω</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:mfrac><mml:mi>e</mml:mi><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:mfrac><mml:mi>s</mml:mi><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:msub><mml:mi>ω</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:msub><mml:mrow><mml:mover><mml:mi>ω</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:mfrac><mml:mi>s</mml:mi><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:msub><mml:mi>ω</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mo>,</mml:mo><mml:mrow><mml:mo fence="true" stretchy="true" symmetric="true" maxsize="2.047em" minsize="2.047em"/></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ12"><label>(11)</label><mml:math id="m12"><mml:mtable columnspacing="5pt" displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>ω</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mi mathvariant="normal">B</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mpadded width="+5pt"><mml:msub><mml:mi>ω</mml:mi><mml:mi mathvariant="normal">B</mml:mi></mml:msub></mml:mpadded></mml:mrow><mml:mo>,</mml:mo><mml:mo mathsize="210%" stretchy="false">.</mml:mo></mml:mrow></mml:mtd><mml:mtd/></mml:mtr></mml:mtable></mml:math></disp-formula><disp-formula id="equ13"><label>(12)</label><mml:math id="m13"><mml:mrow><mml:mtable columnalign="right left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mover><mml:mi>η</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mtext> </mml:mtext><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:msub><mml:mrow><mml:mover><mml:mi>η</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mtext> </mml:mtext><mml:mo>,</mml:mo><mml:mrow><mml:mo fence="true" stretchy="true" symmetric="true" maxsize="2.047em" minsize="2.047em"/></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ14"><label>(13)</label><mml:math id="m14"><mml:mrow><mml:mtable columnalign="right left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mover><mml:mi>η</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">[</mml:mo></mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>ν</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:mfrac><mml:mi>e</mml:mi><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:mfrac><mml:mi>r</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">]</mml:mo></mml:mrow><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:msub><mml:mrow><mml:mover><mml:mi>η</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mo>,</mml:mo><mml:mrow><mml:mo fence="true" stretchy="true" symmetric="true" maxsize="2.047em" minsize="2.047em"/></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ15"><label>(14)</label><mml:math id="m15"><mml:mtable columnspacing="5pt" displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>η</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover><mml:mi mathvariant="normal">Y</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mpadded width="+5pt"><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="normal">Y</mml:mi></mml:msub></mml:mpadded></mml:mrow><mml:mo>,</mml:mo><mml:mo mathsize="210%" stretchy="false">.</mml:mo></mml:mrow></mml:mtd><mml:mtd/></mml:mtr></mml:mtable></mml:math></disp-formula><disp-formula id="equ16"><label>(15)</label><mml:math id="m16"><mml:mrow><mml:mtable columnalign="right left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mover><mml:mi>α</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:mfrac><mml:mi>e</mml:mi><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:mtext> </mml:mtext><mml:mo>,</mml:mo></mml:mtd><mml:mtd><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:msub><mml:mrow><mml:mover><mml:mi>κ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mo>,</mml:mo><mml:mrow><mml:mo fence="true" stretchy="true" symmetric="true" maxsize="2.047em" minsize="2.047em"/></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ17"><label>(16)</label><mml:math id="m17"><mml:mrow><mml:mtable columnalign="right left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mover><mml:mi>λ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:mfrac><mml:mi>s</mml:mi><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">[</mml:mo></mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>ν</mml:mi><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:mfrac><mml:mi>r</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">]</mml:mo></mml:mrow><mml:mtext> </mml:mtext><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:msub><mml:mrow><mml:mover><mml:mi>λ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mo>,</mml:mo><mml:mrow><mml:mo fence="true" stretchy="true" symmetric="true" maxsize="2.047em" minsize="2.047em"/></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ18"><label>(17)</label><mml:math id="m18"><mml:mrow><mml:mtable columnalign="right left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mrow><mml:mover><mml:mi>γ</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>γ</mml:mi><mml:mtext> </mml:mtext><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:msub><mml:mrow><mml:mover><mml:mi>c</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">ϕ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mo>,</mml:mo><mml:mrow><mml:mo fence="true" stretchy="true" symmetric="true" maxsize="2.047em" minsize="2.047em"/></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>where rates without a tilde denote model parameters. A full list of parameters introduced here and their description is provided in <xref ref-type="table" rid="app3table4">Appendix 3—table 4</xref>. This regulatory scheme comprises a multitude of interactions, many of which are simplified effective representations of indirect molecular mechanisms (e.g., through the RANK–RANKL–OPG pathway as described below). In the model building process, the effects of additional regulatory elements (not presented here) were probed and found to be nonessential within the scope of the present modeling aim or nonidentifiable with regard to related parameter values. Specific choices for regulatory interactions were partly based on insights from animal and culture studies and are motivated as follows:</p><list list-type="bullet"><list-item><p><xref ref-type="disp-formula" rid="equ10">Equation 9</xref>: Pre-osteoclasts and pre-osteoblasts are produced at constant rates, a simplifying assumption reflecting the fact that the main function of these populations in the present context is to provide a dynamic reservoir for the rapid supply with active osteoclasts and osteoblasts, respectively.</p></list-item><list-item><p><xref ref-type="disp-formula" rid="equ11">Equation 10</xref>: Estrogen suppresses pre-osteoclast to osteoclast differentiation; a consequence of suppression of RANKL expression (<xref ref-type="bibr" rid="bib89">Streicher et al., 2017</xref>). Sclerostin upregulates pre-osteoclast to osteoclast differentiation; a consequence of upregulation of RANKL expression and downregulation of OPG expression (<xref ref-type="bibr" rid="bib97">Wijenayaka et al., 2011</xref>). Sclerostin downregulates osteoblastogenesis; a consequence of the inhibition of osteoblast differentiation mediated by bone morphogenetic protein 2 (BMP2) and Wnt3a and possibly other pathways (<xref ref-type="bibr" rid="bib98">Winkler et al., 2005</xref>; <xref ref-type="bibr" rid="bib93">Thouverey and Caverzasio, 2015</xref>).</p></list-item><list-item><p><xref ref-type="disp-formula" rid="equ12">Equation 11</xref>: Sclerostin downregulates osteoblast to osteocyte conversion (<xref ref-type="bibr" rid="bib1">Atkins et al., 2011</xref>).</p></list-item><list-item><p><xref ref-type="disp-formula" rid="equ14">Equation 13</xref>: Estrogen and the resorption signal induce osteoclast apoptosis; estrogen has been reported to induce osteoclast apoptosis both directly and mediated by TGFβ (<xref ref-type="bibr" rid="bib34">Kameda et al., 1997</xref>; <xref ref-type="bibr" rid="bib31">Hughes et al., 1996</xref>); TGFβ has been shown to upregulate Bim, a member of the (pro-apoptotic) Bcl2 family (<xref ref-type="bibr" rid="bib30">Houde et al., 2009</xref>).</p></list-item><list-item><p><xref ref-type="disp-formula" rid="equ16">Equation 15</xref>: Estrogen reduces sclerostin production (<xref ref-type="bibr" rid="bib62">Mödder et al., 2011</xref>).</p></list-item><list-item><p><xref ref-type="disp-formula" rid="equ17">Equation 16</xref>: Sclerostin downregulates bone formation (<xref ref-type="bibr" rid="bib49">Li et al., 2008</xref>; <xref ref-type="bibr" rid="bib1">Atkins et al., 2011</xref>). The resorption signal upregulates bone formation; a consequence of TGFβ1 enhancing bone collagen synthesis (<xref ref-type="bibr" rid="bib77">Rydziel et al., 1997b</xref>); furthermore, TGFβ1, skeletal BMPs, and IGF1 have been reported to inhibit collagenase-3 expression in osteoblasts (<xref ref-type="bibr" rid="bib77">Rydziel et al., 1997b</xref>; <xref ref-type="bibr" rid="bib23">Gazzerro et al., 1999</xref>; <xref ref-type="bibr" rid="bib76">Rydziel et al., 1997a</xref>).</p></list-item></list><p>Estrogen concentration is described through its explicit age dependence. Clinical data reported by <xref ref-type="bibr" rid="bib88">Sowers et al., 2008</xref> were used to construct a function capturing the key features of age-dependent decline of serum estradiol levels:<disp-formula id="equ19"><label>(18)</label><mml:math id="m19"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>e</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mn>1</mml:mn></mml:mstyle></mml:mtd><mml:mtd><mml:mi>t</mml:mi><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>τ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mstyle></mml:mtd><mml:mtd><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable><mml:mo fence="true" stretchy="true" symmetric="true"/></mml:mrow><mml:mo>.</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf49"><mml:mi>t</mml:mi></mml:math></inline-formula> denotes time. The parameters <inline-formula><mml:math id="inf50"><mml:msub><mml:mi>t</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf51"><mml:msub><mml:mi>τ</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:msub></mml:math></inline-formula> denote the age at the onset of estradiol decline and a characteristic time scale of the decline, respectively. The time scale <inline-formula><mml:math id="inf52"><mml:msub><mml:mi>τ</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:msub></mml:math></inline-formula> was determined using a fit of the function to the data reported in <xref ref-type="bibr" rid="bib88">Sowers et al., 2008</xref> (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1A</xref>, <xref ref-type="table" rid="app3table4">Appendix 3—table 4</xref>).</p><p>The resorption signal <inline-formula><mml:math id="inf53"><mml:mi>r</mml:mi></mml:math></inline-formula> corresponds to the concentration of bone matrix-derived signaling factors released upon bone resorption. Assuming a release rate proportional to the bone resorption rate <inline-formula><mml:math id="inf54"><mml:msup><mml:mi>b</mml:mi><mml:mo>-</mml:mo></mml:msup></mml:math></inline-formula> and first-order degradation, we consider a highly simplified dynamics of the type <inline-formula><mml:math id="inf55"><mml:mrow><mml:mover accent="true"><mml:mi>r</mml:mi><mml:mo>˙</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mi>b</mml:mi><mml:mo>-</mml:mo></mml:msup><mml:mo>-</mml:mo><mml:mrow><mml:mi>κ</mml:mi><mml:mo>⁢</mml:mo><mml:mi>r</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>, where <inline-formula><mml:math id="inf56"><mml:mi>κ</mml:mi></mml:math></inline-formula> is an effective average degradation rate of the components of the resorption signal. Given that the time scale of degradation, <inline-formula><mml:math id="inf57"><mml:msup><mml:mi>κ</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>, is much shorter (minutes to hours) than the time scale of osteoclast formation and death (weeks), the instantaneous concentration can be approximated to always follow its steady state, <inline-formula><mml:math id="inf58"><mml:mrow><mml:mi>r</mml:mi><mml:mo>≈</mml:mo><mml:mrow><mml:msup><mml:mi>b</mml:mi><mml:mo>-</mml:mo></mml:msup><mml:mo>/</mml:mo><mml:mi>κ</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>, which is proportional to the osteoclast density, <inline-formula><mml:math id="inf59"><mml:mrow><mml:mi>r</mml:mi><mml:mo>∝</mml:mo><mml:msup><mml:mi>b</mml:mi><mml:mo>-</mml:mo></mml:msup><mml:mo>∝</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msup></mml:mrow></mml:math></inline-formula>, via <xref ref-type="disp-formula" rid="equ7">Equation 7</xref>. Since the resorption signal acts as a regulator of bone formation and is rescaled by individual concentration thresholds (see <xref ref-type="disp-formula" rid="equ10">Equation 9</xref>–<xref ref-type="disp-formula" rid="equ18">Equation 17</xref>), the proportionality constant can be absorbed in these thresholds, which enables us to set <inline-formula><mml:math id="inf60"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msup></mml:mrow></mml:math></inline-formula>. Thus, the resorption signal concentration is approximated by the osteoclast density, so that no additional dynamic variable is required.</p><sec sec-type="appendix" id="s9-1"><title>Description of BMD, bone turnover rate, and BTMs</title><p>To compare the model output to clinical data, we relate model variables to clinical observables frequently measured in clinical trials such as BMD and established biomarkers of bone turnover. The BMD follows from the model state as the product of total bone density and BMC:<disp-formula id="equ20"><label>(19)</label><mml:math id="m20"><mml:mrow><mml:mrow><mml:mi>BMD</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>ρ</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mpadded width="+5pt"><mml:msub><mml:mi>c</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:msub></mml:mpadded></mml:mrow></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>In our model, levels of BTMs such as the bone formation markers P1NP and BSAP and the bone resorption marker CTX are related to the rates <inline-formula><mml:math id="inf61"><mml:msup><mml:mi>b</mml:mi><mml:mo>+</mml:mo></mml:msup></mml:math></inline-formula> and <inline-formula><mml:math id="inf62"><mml:msup><mml:mi>b</mml:mi><mml:mo>-</mml:mo></mml:msup></mml:math></inline-formula> of bone formation and resorption, respectively (see <xref ref-type="disp-formula" rid="equ7">Equation 7</xref>). Here, we relate the BTMs P1NP, BSAP, and CTX to bone turnover rates by power laws with marker-specific exponents:<disp-formula id="equ21"><label>(20)</label><mml:math id="m21"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>b</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:msup><mml:mtext> </mml:mtext><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mn>1</mml:mn><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>b</mml:mi><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mn>1</mml:mn><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:msup><mml:mtext> </mml:mtext><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">X</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>b</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msup><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">X</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:msup><mml:mtext> </mml:mtext><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>The exponents <italic>q</italic><sub><italic>x</italic></sub> are obtained as fit parameters using clinical trial data, as described further below.</p><fig id="app1fig1" position="float"><label>Appendix 1—figure 1.</label><caption><title>Parameterization of the aging behavior and creation of hybrid aging/treatment datasets for model calibration and validation.</title><p>(<bold>A</bold>) Age dependence of estradiol serum levels. Clinical data (dots) modified from <xref ref-type="bibr" rid="bib88">Sowers et al., 2008</xref>. The curve shows a fit of the function given by <xref ref-type="disp-formula" rid="equ19">Equation 18</xref> to determine the parameter <italic>τ</italic><sub>e</sub> (<xref ref-type="table" rid="app3table4">Appendix 3—table 4</xref>). (<bold>B</bold>) Bone mineral density (BMD) age dependence for different ethnic groups as indicated. Data modified from <xref ref-type="bibr" rid="bib52">Looker et al., 1998</xref>; reported age bin averages have been used to represent the center of the age bin. (<bold>C</bold>) BMD age dependence shown in panel (<bold>B</bold>), where all curves have been normalized to their earliest value (<italic>t</italic><sub>0</sub> = 25y). (<bold>D</bold>) Schematic of how hybrid aging/treatment datasets were generated by merging the same aging dataset with different treatment datasets; for details, see ‘Methods.’</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76228-app1-fig1-v1.tif"/></fig></sec></sec></app><app id="appendix-2"><title>Appendix 2</title><sec sec-type="appendix" id="s10"><title>Model extensions for medications</title><p>We include a dynamic description of several drug classes through separate model extensions, which depend on the functional drug concentration. The pharmacodynamic description is drug-specific and represents the individual mechanism of action of the respective drug class. For the pharmacokinetic description of each drug, we resort to simple first-order kinetics with drug-specific half-lives, which reduces the amount of model parameters. More detailed pharmacokinetic descriptions involve drug absorption and transfer between different body compartments, depending on the route of administration (oral, intravenous, or subcutaneous). However, simulations of the calibrated model demonstrate that first-order kinetics yields an effective approximation of the pharmacokinetic features essential to capture a drug’s long-term effects on bone remodeling, as suggested by comparisons of simulated and measured BTM concentrations (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1</xref>). A patient’s systemic concentration of a medication is represented by an effective (dimensionless) variable <inline-formula><mml:math id="inf63"><mml:mi>ψ</mml:mi></mml:math></inline-formula> that indicates the relative concentration of the medication. Typically, <inline-formula><mml:math id="inf64"><mml:mi>ψ</mml:mi></mml:math></inline-formula> is given in multiples of a threshold that parameterizes the effect of the drug (such as EC<sub>50</sub>)—the precise interpretation of <inline-formula><mml:math id="inf65"><mml:mi>ψ</mml:mi></mml:math></inline-formula> depends on the model extension that describes the pharmacodynamics of the drug; see ‘Pharmacodynamics for specific medications’.</p><sec sec-type="appendix" id="s10-1"><title>Pharmacokinetics</title><p>The pharmacokinetics of a drug <inline-formula><mml:math id="inf66"><mml:mi>x</mml:mi></mml:math></inline-formula> that is administered in intervals of weeks or months is described by two parameters: the efficacy <inline-formula><mml:math id="inf67"><mml:msub><mml:mi>E</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:math></inline-formula> and the half-life <inline-formula><mml:math id="inf68"><mml:msub><mml:mi>T</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:math></inline-formula>. Given repeated administrations with doses <inline-formula><mml:math id="inf69"><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi mathvariant="normal">…</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> at times <inline-formula><mml:math id="inf70"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi mathvariant="normal">…</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, the efficacy-weighted concentration variable of the drug <inline-formula><mml:math id="inf71"><mml:mi>x</mml:mi></mml:math></inline-formula> therefore follows the exponential kinetics<disp-formula id="equ22"><label>(21)</label><mml:math id="m22"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mi>ψ</mml:mi><mml:mi>x</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>x</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo largeop="true" movablelimits="false" symmetric="true">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover></mml:mstyle><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:msup><mml:mo>⁢</mml:mo><mml:mi mathvariant="normal">Θ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo rspace="7.5pt" stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf72"><mml:mi mathvariant="normal">Θ</mml:mi></mml:math></inline-formula> is the Heaviside function, defined by<disp-formula id="equ23"><mml:math id="m23"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi mathvariant="normal">Θ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mn>0</mml:mn></mml:mstyle></mml:mtd><mml:mtd><mml:mi>t</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mn>1</mml:mn></mml:mstyle></mml:mtd><mml:mtd><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:mtd></mml:mtr></mml:mtable><mml:mo fence="true" stretchy="true" symmetric="true"/></mml:mrow><mml:mo>.</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>Drugs that are administered more frequently (e.g., daily or weekly) are more efficiently captured in a quasi-continuous scheme. The dynamics of BMD and BTM levels is much more inert than such fast administration/degradation dynamics and is well-described by their effective average action. In this quasi-continuous scheme, the drug is considered to be administered at a given average rate for a specified amount of time, so that its concentration evolves according to the dynamic equation<disp-formula id="equ24"><label>(22)</label><mml:math id="m24"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>ψ</mml:mi><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi mathvariant="normal">Θ</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mi mathvariant="normal">Θ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:msub><mml:mi>ψ</mml:mi><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>with initial condition <inline-formula><mml:math id="inf73"><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:msub><mml:mi>ψ</mml:mi><mml:mi>x</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo fence="true" stretchy="false">|</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>→</mml:mo><mml:mrow><mml:mo>-</mml:mo><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>, where <italic>c</italic><sub><italic>i</italic></sub> are doses per unit time, and where <italic>t</italic><sub><italic>i</italic></sub> and <inline-formula><mml:math id="inf74"><mml:msubsup><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mo>*</mml:mo></mml:msubsup></mml:math></inline-formula> are the start and end times of a treatment period, respectively. (Numerically, the quasi-continuous scheme has the advantage that model simulations do not have to resort to extremely small integration time steps to capture the details of short-term drug degradation, which considerably improves runtime.)</p><p>Different drugs <inline-formula><mml:math id="inf75"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi mathvariant="normal">…</mml:mi></mml:mrow></mml:math></inline-formula> of the same class (sclerostin inhibitors, bisphosphonates, PTH analogs, etc.) are considered through an effective concentration equivalent that is the sum of the efficacy-weighted doses of different drugs:<disp-formula id="equ25"><label>(23)</label><mml:math id="m25"><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Ψ</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munder><mml:mo largeop="true" movablelimits="false" symmetric="true">∑</mml:mo><mml:mi>i</mml:mi></mml:munder></mml:mstyle><mml:mrow><mml:msub><mml:mi>ψ</mml:mi><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo rspace="7.5pt" stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where the <inline-formula><mml:math id="inf76"><mml:msub><mml:mi>ψ</mml:mi><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msub></mml:math></inline-formula> are given by <xref ref-type="disp-formula" rid="equ22">Equation 21</xref> in the case of discrete doses and <xref ref-type="disp-formula" rid="equ24">Equation 22</xref> in the case of quasi-continuous dosing.</p></sec><sec sec-type="appendix" id="s10-2"><title>Pharmacodynamics for specific medications</title><p>We now introduce separate model extensions that embody the essential mechanisms of action of different drug classes.</p><sec sec-type="appendix" id="s10-2-1"><title>RANKL antibodies</title><p>Denosumab is a monoclonal antibody (mAb) that binds with affinity to receptor activator of NF-<inline-formula><mml:math id="inf77"><mml:mi>κ</mml:mi></mml:math></inline-formula>B ligand (RANKL) and blocks its interactions with RANK (<xref ref-type="bibr" rid="bib40">Kostenuik et al., 2009</xref>), which, in turn, decreases osteoclast formation (<xref ref-type="bibr" rid="bib11">Boyce and Xing, 2008</xref>). Moreover, denosumab has been suggested to enable increased bone tissue mineralization, which leads not only to a halt of the BMD decline but also to a long-term increase in BMD (<xref ref-type="bibr" rid="bib83">Scheiner et al., 2014</xref>). We include these mechanisms in our model through a modification of the reference pre-osteoclast differentiation rate <inline-formula><mml:math id="inf78"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>ω</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> to include a downregulation by denosumab and the steady-state BMC <italic>c</italic><sub>0</sub> to include an upregulation through denosumab in <xref ref-type="disp-formula" rid="equ11">Equation 10</xref> and <xref ref-type="disp-formula" rid="equ18">Equation 17</xref>, respectively:<disp-formula id="equ26"><label>(24)</label><mml:math id="m26"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>ω</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo stretchy="false">→</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msubsup><mml:mi>β</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">Ψ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:msub><mml:mi>ω</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo stretchy="false">→</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>β</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">Ψ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mtext> </mml:mtext><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf79"><mml:msub><mml:mi mathvariant="normal">Ψ</mml:mi><mml:mi>rAb</mml:mi></mml:msub></mml:math></inline-formula> is the RANKL antibody concentration in multiples of the half-maximal effective concentration (<italic>EC</italic><sub>50</sub>), determined through <xref ref-type="disp-formula" rid="equ22">Equation 21</xref> and <xref ref-type="disp-formula" rid="equ25">Equation 23</xref>. For simplicity, <italic>EC</italic><sub>50</sub> for the regulation of both differentiation and mineralization are taken to be identical, which is justified a posteriori by showing its effectivity in approximating the drug action. The scaling factors <inline-formula><mml:math id="inf80"><mml:msubsup><mml:mi>β</mml:mi><mml:msup><mml:mi mathvariant="normal">C</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mi>rAb</mml:mi></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="inf81"><mml:msubsup><mml:mi>β</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi>rAb</mml:mi></mml:msubsup></mml:math></inline-formula> parameterize the respective maximum effect strength and are subject to the constraints <inline-formula><mml:math id="inf82"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>β</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf83"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>β</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> to ensure positive rates and BMCs between 0 and 100%.</p></sec><sec sec-type="appendix" id="s10-2-2"><title>Sclerostin antibodies</title><p>Romosozumab and blosozumab are mAbs that bind to sclerostin and prevent its inhibitory effects on bone formation (<xref ref-type="bibr" rid="bib72">Recknor et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Lim and Bolster, 2017</xref>; <xref ref-type="bibr" rid="bib61">McClung et al., 2018</xref>). (Note that blosozumab was not approved for osteoporosis treatment at the time this manuscript was written.) Accordingly, we represent the mechanism of action of sclerostin antibodies by adding a new variable <inline-formula><mml:math id="inf84"><mml:msup><mml:mi>s</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:math></inline-formula> corresponding to the level of antibody-bound sclerostin and adding the dynamics of antibody-binding and unbinding in <xref ref-type="disp-formula" rid="equ6">Equation 6</xref>,<disp-formula id="equ27"><label>(25)</label><mml:math id="m27"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mrow><mml:mover><mml:mi>s</mml:mi><mml:mo>˙</mml:mo></mml:mover></mml:mrow></mml:mtd><mml:mtd><mml:mo stretchy="false">→</mml:mo><mml:mrow><mml:mover><mml:mi>s</mml:mi><mml:mo>˙</mml:mo></mml:mover></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi mathvariant="normal">Ψ</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:mrow></mml:msub><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>s</mml:mi><mml:mo>∗</mml:mo></mml:msup><mml:mtext> </mml:mtext><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msup><mml:mrow><mml:mover><mml:mi>s</mml:mi><mml:mo>˙</mml:mo></mml:mover></mml:mrow><mml:mo>∗</mml:mo></mml:msup></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi mathvariant="normal">Ψ</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:mrow></mml:msub><mml:mi>s</mml:mi><mml:mo>−</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mi>s</mml:mi><mml:mo>∗</mml:mo></mml:msup><mml:mtext> </mml:mtext><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf85"><mml:msub><mml:mi mathvariant="normal">Ψ</mml:mi><mml:mi>sAb</mml:mi></mml:msub></mml:math></inline-formula> is the effective sclerostin antibody concentration equivalent determined through <xref ref-type="disp-formula" rid="equ22">Equation 21</xref> and <xref ref-type="disp-formula" rid="equ25">Equation 23</xref>. Here, <inline-formula><mml:math id="inf86"><mml:msub><mml:mi>κ</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:msub></mml:math></inline-formula> denotes the sclerostin degradation rate and <inline-formula><mml:math id="inf87"><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:msub></mml:math></inline-formula> is the sclerostin/antibody binding rate; this parameterization implies that <inline-formula><mml:math id="inf88"><mml:msub><mml:mi mathvariant="normal">Ψ</mml:mi><mml:mi>sAb</mml:mi></mml:msub></mml:math></inline-formula> is given in multiples of the effective antibody levels needed to achieve a binding rate equal to the unperturbed degradation grade of sclerostin.</p></sec><sec sec-type="appendix" id="s10-2-3"><title>Bisphosphonates</title><p>Bisphosphonates (like alendronate, ibandronate, risedronate, and zoledronate) bind to hydroxyapatite on the bone surface, thereby preventing osteoclasts from bone resorption; they further inhibit osteoclast-mediated bone resorption by promoting osteoclast apoptosis (<xref ref-type="bibr" rid="bib80">Sato et al., 1991</xref>; <xref ref-type="bibr" rid="bib74">Rodan and Fleisch, 1996</xref>). To simplify the model extension, we effectively represent the mechanism of action of bisphosphonates through the upregulation of the osteoclast apoptosis rate in <xref ref-type="disp-formula" rid="equ14">Equation 13</xref>:<disp-formula id="equ28"><label>(26)</label><mml:math id="m28"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">→</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">Ψ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msubsup><mml:mi>η</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:mtext> </mml:mtext><mml:mo>,</mml:mo></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf89"><mml:msub><mml:mi mathvariant="normal">Ψ</mml:mi><mml:mi>bp</mml:mi></mml:msub></mml:math></inline-formula> is the effective bisphosphonate concentration equivalent determined through <xref ref-type="disp-formula" rid="equ24">Equation 22</xref> and <xref ref-type="disp-formula" rid="equ25">Equation 23</xref>, and <inline-formula><mml:math id="inf90"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>η</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> is the maximum additional apoptosis rate caused by the presence of bisphosphonates.</p></sec><sec sec-type="appendix" id="s10-2-4"><title>PTH analogs</title><p>Teriparatide and abaloparatide are recombinant human PTH analogs (<xref ref-type="bibr" rid="bib32">Jiang et al., 2003</xref>; <xref ref-type="bibr" rid="bib27">Hattersley et al., 2016</xref>). PTH is known to have an anabolic effect on bone if administered intermittently while exerting a catabolic effect if administered continuously (<xref ref-type="bibr" rid="bib91">Tam et al., 1982</xref>; <xref ref-type="bibr" rid="bib29">Hock and Gera, 1992</xref>). Here, we consider an effective representation of the action of PTH in the anabolic regime only; this leads to a highly simplified and efficient description of the effective action of PTH therapies on bone turnover. However, it implies that the scope of our model is restricted to anabolic administration schemes and cannot be expected to yield correct results if probed in inappropriate regimes. In the anabolic regime, teriparatide downregulates osteoblast apoptosis (<xref ref-type="bibr" rid="bib33">Jilka et al., 1999</xref>). Moreover, bone turnover markers show a marked increase early after treatment start but decline while drug administration remains unaltered (<xref ref-type="bibr" rid="bib43">Leder et al., 2014</xref>, see <xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1</xref>); such an effect is achieved in our model by rapid upregulation of osteoclast/osteoblast differentiation. We therefore also include a regulatory effect on osteoclast differentiation (which indirectly affects osteoblast differentiation as well):<disp-formula id="equ29"><label>(27)</label><mml:math id="m29"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo stretchy="false">→</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msubsup><mml:mi>β</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">Ψ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>ω</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo stretchy="false">→</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>β</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">Ψ</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:msub><mml:mi>ω</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf91"><mml:msub><mml:mi mathvariant="normal">Ψ</mml:mi><mml:mi>pth</mml:mi></mml:msub></mml:math></inline-formula> is the effective teriparatide concentration equivalent determined through <xref ref-type="disp-formula" rid="equ24">Equation 22</xref> and <xref ref-type="disp-formula" rid="equ25">Equation 23</xref>, and the parameters <inline-formula><mml:math id="inf92"><mml:msubsup><mml:mi>β</mml:mi><mml:mi mathvariant="normal">B</mml:mi><mml:mi>pth</mml:mi></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="inf93"><mml:msubsup><mml:mi>β</mml:mi><mml:msup><mml:mi mathvariant="normal">C</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mi>pth</mml:mi></mml:msubsup></mml:math></inline-formula> parameterize the maximum effect strength of osteoblast apoptosis and pre-osteoclast differentiation, respectively.</p></sec></sec></sec></app><app id="appendix-3"><title>Appendix 3</title><sec sec-type="appendix" id="s11"><title>Simulations and parameter fits</title><sec sec-type="appendix" id="s11-1"><title>Simulation protocol for aging and treatment</title><p>A model simulation was implemented in Python using standard NumPy and SciPy packages (<xref ref-type="bibr" rid="bib65">Oliphant, 2006</xref>; <xref ref-type="bibr" rid="bib95">Virtanen et al., 2020</xref>) and solved using SciPy’s ‘solve_ivp’ function with BDF solver. To compare how the model predicts the bone turnover dynamics of a hybrid aging/treatment dataset (see ‘Methods’ and <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1D</xref>) for a given set of model parameters, simulations were structured as follows. Drug dosing information of the corresponding dataset was provided to the model through the set of administered doses and the administration times: For the case of discrete dosing, dosing information consisted of doses <italic>c</italic><sub><italic>i</italic></sub> and administration times <italic>t</italic><sub><italic>i</italic></sub> entering <xref ref-type="disp-formula" rid="equ22">Equation 21</xref> (used for the drugs blosozumab, romosozumab, and denosumab). For the case of quasi-continuous dosing, dosing information consisted of doses per unit time <italic>c</italic><sub><italic>i</italic></sub> and time windows <inline-formula><mml:math id="inf94"><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:math></inline-formula> entering <xref ref-type="disp-formula" rid="equ24">Equation 22</xref> (used for the drugs alendronate and teriparatide).</p><p>The model was initialized at <inline-formula><mml:math id="inf95"><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula> in its steady state for all dynamic variables (i.e., the state for which all time derivatives are zero); except for the bone density <inline-formula><mml:math id="inf96"><mml:msub><mml:mi>ρ</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:msub></mml:math></inline-formula>, which does not possess a unique steady state and which was set to unity to represent peak bone density. We then simulated the model until well after the treatment period. All aging-related effects in the model were mediated by explicitly time-dependent auxiliary functions, as explained in Appendix 1 . To compare simulation results with clinical data, all relevant model variables were rescaled such that the first recorded data point in the corresponding clinical dataset coincided with the corresponding time point in the simulation, so that relative changes from a reference time point could be compared.</p></sec><sec sec-type="appendix" id="s11-2"><title>Parameter fits</title><p>To systematically fit model parameters, we defined a cost function that takes into account multiple fit quantities depending on their availability in the datasets. For a hybrid dataset <inline-formula><mml:math id="inf97"><mml:mi>α</mml:mi></mml:math></inline-formula> and clinical quantity <inline-formula><mml:math id="inf98"><mml:mi>β</mml:mi></mml:math></inline-formula> (BMD and serum levels of CTX, P1NP, and BSAP), we defined the distance function<disp-formula id="equ30"><label>(28)</label><mml:math id="m30"><mml:mrow><mml:mrow><mml:msup><mml:mi>D</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>⁢</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mo largeop="true" symmetric="true">∑</mml:mo><mml:mi>i</mml:mi></mml:msub><mml:msubsup><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>⁢</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>⁢</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munder><mml:mo largeop="true" movablelimits="false" symmetric="true">∑</mml:mo><mml:mi>i</mml:mi></mml:munder></mml:mstyle><mml:mrow><mml:msubsup><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>⁢</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:msubsup><mml:mo>⁢</mml:mo><mml:msubsup><mml:mi>z</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>⁢</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:msubsup><mml:mo>⁢</mml:mo><mml:mpadded width="+5pt"><mml:msup><mml:mrow><mml:mo maxsize="160%" minsize="160%">(</mml:mo><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>⁢</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>i</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>⁢</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo maxsize="160%" minsize="160%">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mpadded></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mo>,</mml:mo><mml:mo mathsize="210%" stretchy="false">.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where <italic>x</italic><sub><italic>i</italic></sub> denotes the clinical data point at time point <inline-formula><mml:math id="inf99"><mml:mi>i</mml:mi></mml:math></inline-formula>, <inline-formula><mml:math id="inf100"><mml:msub><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula> denotes the respective simulated data point, <italic>w</italic><sub><italic>i</italic></sub> denotes the relative weight of the respective data point depending on its certainty, and <italic>z</italic><sub><italic>i</italic></sub> denotes the relative weight depending on the time interval represented by the respective data point. For BTMs, we used the weights <inline-formula><mml:math id="inf101"><mml:mrow><mml:msubsup><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>⁢</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msubsup><mml:mi>e</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>⁢</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>, where <inline-formula><mml:math id="inf102"><mml:msubsup><mml:mi>e</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>⁢</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> is the mean of the upper and lower error bars of the respective quantity <inline-formula><mml:math id="inf103"><mml:mi>β</mml:mi></mml:math></inline-formula>; for the BMD, we used unit weights (<inline-formula><mml:math id="inf104"><mml:mrow><mml:msubsup><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>BMD</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>). To account for the fact that time intervals between data points may vastly differ (e.g., between the coarsely sampled aging dataset and the densely sampled treatment datasets), we included an interval-dependent weighting factor <italic>z</italic><sub><italic>i</italic></sub>, such that each data point was weighted by the average distance to its neighboring data points: The time interval-related weighting factors <inline-formula><mml:math id="inf105"><mml:msubsup><mml:mi>z</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>⁢</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> were defined as <inline-formula><mml:math id="inf106"><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="inf107"><mml:mrow><mml:mn>1</mml:mn><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>≤</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula>), where <inline-formula><mml:math id="inf108"><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="inf109"><mml:mrow><mml:mn>1</mml:mn><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>≤</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>), <inline-formula><mml:math id="inf110"><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="inf111"><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <italic>t</italic><sub><italic>i</italic></sub> denotes the time point of measurement <inline-formula><mml:math id="inf112"><mml:mi>i</mml:mi></mml:math></inline-formula>.</p><p>We defined the combined cost function over all considered datasets as<disp-formula id="equ31"><label>(29)</label><mml:math id="m31"><mml:mrow><mml:mrow><mml:mi>J</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munder><mml:mo largeop="true" movablelimits="false" symmetric="true">∑</mml:mo><mml:mrow><mml:mi>α</mml:mi><mml:mo>⁢</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:munder></mml:mstyle><mml:mrow><mml:msup><mml:mi>W</mml:mi><mml:mi>β</mml:mi></mml:msup><mml:mo>⁢</mml:mo><mml:mpadded width="+5pt"><mml:msup><mml:mi>D</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>⁢</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:msup></mml:mpadded></mml:mrow></mml:mrow></mml:mrow><mml:mo>,</mml:mo><mml:mo mathsize="210%" stretchy="false">.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf113"><mml:msup><mml:mi>W</mml:mi><mml:mi>β</mml:mi></mml:msup></mml:math></inline-formula> is an additional weighting factor that determines the relative importance of the different fit quantities in the cost function (<xref ref-type="table" rid="app3table1">Appendix 3—table 1</xref>).</p><p>In a first step, all fit parameters were manually adjusted for the model to exhibit a roughly sensible aging behavior. In a second step, a selected subset of hybrid aging/treatment datasets (see ‘Methods’ and <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1D</xref>) were used to fit all free model parameters. To perform the fits, we used a Covariance Matrix Adaptation Evolution Strategy via the Python package ‘pycma’ (<xref ref-type="bibr" rid="bib26">Hansen et al., 2019</xref>). Results of the parameter fits are shown in <xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1</xref>. The full list of fit parameters, including their final fit values, is given in <xref ref-type="table" rid="app3table4">Appendix 3—table 4</xref>.</p><table-wrap id="app3table1" position="float"><label>Appendix 3—table 1.</label><caption><title>Values of fit weights <inline-formula><mml:math id="inf114"><mml:msup><mml:mi>W</mml:mi><mml:mi>β</mml:mi></mml:msup></mml:math></inline-formula> used in <xref ref-type="disp-formula" rid="equ31">Equation 29</xref>.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Weight</th><th align="left" valign="bottom">Value</th></tr></thead><tbody><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf115"><mml:msup><mml:mi>W</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>BMD</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">300</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf116"><mml:msup><mml:mi>W</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>CTX</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf117"><mml:msup><mml:mi>W</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>P1NP</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf118"><mml:msup><mml:mi>W</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>BSAP</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="char" char="." valign="bottom">1</td></tr></tbody></table><table-wrap-foot><fn><p>BMD, bone mineral density; CTX, C-terminal telopeptide; P1NP, procollagen type 1 amino-terminal propeptide; BSAP, bone-specific alkaline phosphatase</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="appendix" id="s11-3"><title>Goodness-of-fit measures</title><p>To assess the goodness of the parameter fit and model predictions, we considered complementary goodness measures. The MAPE between clinical and simulated results is defined by<disp-formula id="equ32"><label>(30)</label><mml:math id="m32"><mml:mrow><mml:mrow><mml:msub><mml:mi>G</mml:mi><mml:mi>MAPE</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac></mml:mstyle><mml:mo>⁢</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo largeop="true" movablelimits="false" symmetric="true">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover></mml:mstyle><mml:mpadded width="+5pt"><mml:mstyle displaystyle="true"><mml:mfrac><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfrac></mml:mstyle></mml:mpadded></mml:mrow></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where the sum runs over all clinically recorded time points for the respective quantity (baseline changes of BMD and BTM levels), <italic>x</italic><sub><italic>i</italic></sub> denotes the clinical data point, <italic>t</italic><sub><italic>i</italic></sub> the time it was taken, and <inline-formula><mml:math id="inf119"><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> denotes the model result, which is a continuous function of time.</p><p>As a complementary measure, we introduce a ‘windowed minimal absolute percentage error’ (WMAPE), which indicates the mean minimal distance between model results and the data within a time window around the data point that reflects the average time spacing between data points. Formally, the WMAPE is given by<disp-formula id="equ33"><label>(31)</label><mml:math id="m33"><mml:mrow><mml:mrow><mml:msub><mml:mi>G</mml:mi><mml:mi>WMAPE</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac></mml:mstyle><mml:mo>⁢</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo largeop="true" movablelimits="false" symmetric="true">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover></mml:mstyle><mml:mrow><mml:mstyle displaystyle="true"><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfrac></mml:mstyle><mml:mo>⁢</mml:mo><mml:mrow><mml:munder><mml:mi>min</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>∈</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:mi>τ</mml:mi></mml:mrow><mml:mo>,</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>τ</mml:mi></mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:munder><mml:mo>⁡</mml:mo><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mo rspace="7.5pt" stretchy="false">|</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>Here, we choose the time window <inline-formula><mml:math id="inf120"><mml:mi>τ</mml:mi></mml:math></inline-formula> as half the median distance between data points, <inline-formula><mml:math id="inf121"><mml:mrow><mml:mi>τ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mi>median</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>⁡</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>.</p><table-wrap id="app3table2" position="float"><label>Appendix 3—table 2.</label><caption><title>Data sources used to calibrate and validate the model.</title><p>Columns titled ‘Figure(s)’ indicate the plot panels in the respective publication that were digitized. BMD always refers to total hip bone mineral density.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2">Publication</th><th align="left" valign="bottom" rowspan="2">Medication(s)</th><th align="left" valign="bottom" rowspan="2">Dosings</th><th align="left" valign="bottom" colspan="4">Figure(s)</th><th align="left" valign="bottom">Table(s)</th></tr><tr><th align="left" valign="bottom">BMD</th><th align="left" valign="bottom">CTX</th><th align="left" valign="bottom">P1NP</th><th align="left" valign="bottom">BSAP</th><th align="left" valign="bottom">BMD</th></tr></thead><tbody><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib7">Black et al., 2006</xref></td><td align="left" valign="bottom">Alendronate</td><td align="char" char="ndash" valign="bottom">5–10 mg Q1D</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib9">Bone et al., 2011</xref></td><td align="left" valign="bottom">Denosumab</td><td align="char" char="." valign="bottom">60 mg Q6M</td><td align="char" char="." valign="bottom">3b</td><td align="char" char="." valign="bottom">4b</td><td align="char" char="." valign="bottom">4a</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib17">Cosman et al., 2016</xref></td><td align="left" valign="bottom">Romosozumab</td><td align="char" char="." valign="bottom">210 mg Q1M</td><td align="char" char="." valign="bottom">3b</td><td align="char" char="." valign="bottom">3e</td><td align="char" char="." valign="bottom">3d</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Denosumab</td><td align="char" char="." valign="bottom">60 mg Q6M</td><td align="char" char="." valign="bottom">3b</td><td align="char" char="." valign="bottom">3e</td><td align="char" char="." valign="bottom">3d</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib43">Leder et al., 2014</xref></td><td align="left" valign="bottom">Teriparatide</td><td align="char" char="." valign="bottom">20 mcg Q1D</td><td align="char" char="." valign="bottom">2d</td><td align="char" char="." valign="bottom">4c,f</td><td align="char" char="." valign="bottom">4b,e</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib44">Leder et al., 2015</xref></td><td align="left" valign="bottom">Teriparatide</td><td align="char" char="." valign="bottom">20 mcg Q1D</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Denosumab</td><td align="char" char="." valign="bottom">60 mg Q6M</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Lewiecki et al., 2019</xref></td><td align="left" valign="bottom">Romosozumab</td><td align="char" char="." valign="bottom">210 mg Q1M</td><td align="char" char="." valign="bottom">3b</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Denosumab</td><td align="char" char="." valign="bottom">60 mg Q6M</td><td align="char" char="." valign="bottom">3b</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib52">Looker et al., 1998</xref></td><td align="left" valign="bottom">[Age-dependent BMD]</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="char" char="." valign="bottom">7</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib59">McClung et al., 2006</xref></td><td align="left" valign="bottom">Denosumab</td><td align="left" valign="bottom">6 mg Q3M, 14 mg Q6M, 210 mg Q6M</td><td align="char" char="." valign="bottom">2b</td><td align="char" char="." valign="bottom">2e</td><td align="left" valign="bottom">—</td><td align="char" char="." valign="bottom">2f</td><td align="left" valign="bottom">—</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib60">McClung et al., 2017</xref></td><td align="left" valign="bottom">Denosumab</td><td align="char" char="ndash" valign="bottom">6–14 mg Q3M, 14–210 mg Q6M</td><td align="char" char="." valign="bottom">2b</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib61">McClung et al., 2018</xref></td><td align="left" valign="bottom">Romosozumab</td><td align="char" char="." valign="bottom">140 mg Q1M, 210 mg Q1M</td><td align="char" char="." valign="bottom">3c</td><td align="char" char="." valign="bottom">4b</td><td align="char" char="." valign="bottom">4a</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Denosumab</td><td align="char" char="." valign="bottom">60 mg Q6M</td><td align="char" char="." valign="bottom">3c,d</td><td align="char" char="." valign="bottom">4b,d</td><td align="char" char="." valign="bottom">4a,c</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Alendronate</td><td align="char" char="." valign="bottom">70 mg Q1W</td><td align="char" char="." valign="bottom">3d</td><td align="char" char="." valign="bottom">4d</td><td align="char" char="." valign="bottom">4c</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib72">Recknor et al., 2015</xref></td><td align="left" valign="bottom">Blosozumab</td><td align="left" valign="bottom">180 mg Q4W, 180 mg Q2W, 270 mg Q2W</td><td align="char" char="." valign="bottom">3b</td><td align="char" char="." valign="bottom">4d</td><td align="char" char="." valign="bottom">4a</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib79">Saag et al., 2017</xref></td><td align="left" valign="bottom">Alendronate</td><td align="char" char="." valign="bottom">70 mg Q1W</td><td align="char" char="." valign="bottom">3b</td><td align="char" char="." valign="bottom">3d</td><td align="char" char="." valign="bottom">3c</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td></tr></tbody></table><table-wrap-foot><fn><p>Q, every; M, month; D, day; W, week; CTX, C-terminal telopeptide; P1NP, procollagen type 1 amino-terminal propeptide; BSAP, bone-specific alkaline phosphatase.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app3table3" position="float"><label>Appendix 3—table 3.</label><caption><title>Goodness-of-fit measures for calibration and validation datasets.</title><p>Mean absolute percentage error (MAPE) and windowed minimal absolute percentage error (WMAPE) as defined in <xref ref-type="disp-formula" rid="equ32">Equation 30</xref> and <xref ref-type="disp-formula" rid="equ33">Equation 31</xref>, respectively. The column ‘Shown in’ indicates the figure in this article that shows the respective simulation and data plot.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2">Medication(s)</th><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="4">MAPE</th><th align="left" valign="bottom" colspan="4">WMAPE</th><th align="left" valign="bottom" rowspan="2">Shown in</th></tr><tr><th align="left" valign="bottom">Data ref.</th><th align="left" valign="bottom">BMD (%)</th><th align="left" valign="bottom">CTX (%)</th><th align="left" valign="bottom">P1NP (%)</th><th align="left" valign="bottom">BSAP (%)</th><th align="left" valign="bottom">BMD (%)</th><th align="left" valign="bottom">CTX (%)</th><th align="left" valign="bottom">P1NP (%)</th><th align="left" valign="bottom">BSAP (%)</th></tr><tr><th align="left" valign="bottom" colspan="11">Calibration datasets</th></tr></thead><tbody><tr><td align="left" valign="bottom">Alendronate 5–10 mg Q1D</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib7">Black et al., 2006</xref></td><td align="left" valign="bottom">0.9</td><td align="left" valign="bottom">7.0</td><td align="left" valign="bottom">21.1</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.6</td><td align="left" valign="bottom">4.7</td><td align="left" valign="bottom">13.5</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1</xref></td></tr><tr><td align="left" valign="bottom">Alendronate 70 mg Q1W</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib79">Saag et al., 2017</xref></td><td align="left" valign="bottom">0.5</td><td align="left" valign="bottom">34.4</td><td align="left" valign="bottom">13.7</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.2</td><td align="left" valign="bottom">20.3</td><td align="left" valign="bottom">10.2</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1</xref></td></tr><tr><td align="left" valign="bottom">Blosozumab 180 mg Q4W</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib72">Recknor et al., 2015</xref></td><td align="left" valign="bottom">0.7</td><td align="left" valign="bottom">16.5</td><td align="left" valign="bottom">23.8</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.4</td><td align="left" valign="bottom">10.8</td><td align="left" valign="bottom">18.7</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1</xref></td></tr><tr><td align="left" valign="bottom">Blosozumab 270 mg Q2W</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib72">Recknor et al., 2015</xref></td><td align="left" valign="bottom">0.3</td><td align="left" valign="bottom">26.8</td><td align="left" valign="bottom">13.2</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.2</td><td align="left" valign="bottom">15.8</td><td align="left" valign="bottom">4.8</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1</xref></td></tr><tr><td align="left" valign="bottom">Denosumab 14 mg Q3M<break/>→<break/><break/>denosumab 60 mg Q6M</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib60">McClung et al., 2017</xref></td><td align="left" valign="bottom">0.3</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.1</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1</xref></td></tr><tr><td align="left" valign="bottom">Denosumab 14 mg Q6M</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib59">McClung et al., 2006</xref></td><td align="left" valign="bottom">0.2</td><td align="left" valign="bottom">73.9</td><td align="left" valign="bottom">—</td><td align="char" char="." valign="bottom">17.0</td><td align="left" valign="bottom">0.0</td><td align="left" valign="bottom">46.3</td><td align="left" valign="bottom">—</td><td align="char" char="." valign="bottom">0.2</td><td align="left" valign="bottom"><xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1</xref></td></tr><tr><td align="left" valign="bottom">Placebo</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib72">Recknor et al., 2015</xref></td><td align="left" valign="bottom">0.4</td><td align="left" valign="bottom">7.3</td><td align="left" valign="bottom">15.4</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.3</td><td align="left" valign="bottom">7.2</td><td align="left" valign="bottom">15.3</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1</xref></td></tr><tr><td align="left" valign="bottom">Teriparatide 20 mcg Q1D</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib43">Leder et al., 2014</xref></td><td align="left" valign="bottom">0.4</td><td align="left" valign="bottom">17.1</td><td align="left" valign="bottom">8.5</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.2</td><td align="left" valign="bottom">9.1</td><td align="left" valign="bottom">1.6</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1</xref></td></tr><tr><td align="left" valign="bottom">Teriparatide 20 mcg Q1D→<break/>denosumab 60 mg Q6M</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib44">Leder et al., 2015</xref></td><td align="left" valign="bottom">0.4</td><td align="left" valign="bottom">65.5</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.2</td><td align="left" valign="bottom">8.6</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="app3fig1">Appendix 3—figure 1</xref></td></tr><tr><th align="left" valign="bottom" colspan="11">Validation datasets</th></tr><tr><td align="left" valign="bottom">Alendronate 70 mg Q1W<break/>→<break/>romosozumab 140 mg Q1M<break/>→<break/>denosumab 60 mg Q6M</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib61">McClung et al., 2018</xref></td><td align="left" valign="bottom">0.5</td><td align="left" valign="bottom">25.4</td><td align="left" valign="bottom">20.0</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.3</td><td align="left" valign="bottom">17.1</td><td align="left" valign="bottom">3.6</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2</xref></td></tr><tr><td align="left" valign="bottom">Blosozumab 180 mg Q2W</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib72">Recknor et al., 2015</xref></td><td align="left" valign="bottom">0.3</td><td align="left" valign="bottom">21.3</td><td align="left" valign="bottom">20.3</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.1</td><td align="left" valign="bottom">13.2</td><td align="left" valign="bottom">12.6</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2</xref></td></tr><tr><td align="left" valign="bottom">Denosumab 60 mg Q6M<break/>→<break/>teriparatide 20 mcg Q1D</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib44">Leder et al., 2015</xref></td><td align="left" valign="bottom">0.4</td><td align="left" valign="bottom">103.1</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.3</td><td align="left" valign="bottom">44.6</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2</xref></td></tr><tr><td align="left" valign="bottom">Placebo</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib61">McClung et al., 2018</xref></td><td align="left" valign="bottom">0.6</td><td align="left" valign="bottom">6.2</td><td align="left" valign="bottom">10.5</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.5</td><td align="left" valign="bottom">6.2</td><td align="left" valign="bottom">10.5</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2</xref></td></tr><tr><td align="left" valign="bottom">Placebo→<break/>denosumab 60 mg Q6M</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib61">McClung et al., 2018</xref></td><td align="left" valign="bottom">0.6</td><td align="left" valign="bottom">13.2</td><td align="left" valign="bottom">10.1</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.4</td><td align="left" valign="bottom">5.1</td><td align="left" valign="bottom">7.4</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2</xref></td></tr><tr><td align="left" valign="bottom">Teriparatide 20 mcg Q1D + denosumab 60 mg Q6M<break/>→<break/>denosumab 60 mg Q6M</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib44">Leder et al., 2015</xref></td><td align="left" valign="bottom">0.7</td><td align="left" valign="bottom">183.7</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.4</td><td align="left" valign="bottom">66.4</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2">Figure 2</xref></td></tr><tr><td align="left" valign="bottom">Alendronate 70 mg Q1W<break/>→<break/>romosozumab 140 mg Q1M<break/>→<break/>placebo</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib61">McClung et al., 2018</xref></td><td align="left" valign="bottom">0.5</td><td align="left" valign="bottom">22.9</td><td align="left" valign="bottom">16.8</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.4</td><td align="left" valign="bottom">15.1</td><td align="left" valign="bottom">4.2</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref></td></tr><tr><td align="left" valign="bottom">Placebo→<break/>denosumab 60 mg Q6M</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib17">Cosman et al., 2016</xref></td><td align="left" valign="bottom">0.5</td><td align="left" valign="bottom">81.9</td><td align="left" valign="bottom">9.6</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.0</td><td align="left" valign="bottom">44.4</td><td align="left" valign="bottom">4.0</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref></td></tr><tr><td align="left" valign="bottom">Placebo→<break/>denosumab 60 mg Q6M</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Lewiecki et al., 2019</xref></td><td align="left" valign="bottom">0.4</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.1</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref></td></tr><tr><td align="left" valign="bottom">Placebo→<break/>denosumab 60 mg Q6M</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib60">McClung et al., 2017</xref></td><td align="left" valign="bottom">0.6</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.3</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref></td></tr><tr><td align="left" valign="bottom">Romosozumab 210 mg Q1M<break/>→<break/>alendronate 70 mg Q1W</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib79">Saag et al., 2017</xref></td><td align="left" valign="bottom">1.0</td><td align="left" valign="bottom">30.0</td><td align="left" valign="bottom">37.1</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.5</td><td align="left" valign="bottom">19.4</td><td align="left" valign="bottom">11.7</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref></td></tr><tr><td align="left" valign="bottom">Romosozumab 210 mg Q1M<break/>→<break/>denosumab 60 mg Q6M</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib17">Cosman et al., 2016</xref></td><td align="left" valign="bottom">1.2</td><td align="left" valign="bottom">92.5</td><td align="left" valign="bottom">22.4</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.6</td><td align="left" valign="bottom">50.7</td><td align="left" valign="bottom">6.9</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref></td></tr><tr><td align="left" valign="bottom">Romosozumab 210 mg Q1M<break/>→<break/>denosumab 60 mg Q6M</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Lewiecki et al., 2019</xref></td><td align="left" valign="bottom">1.0</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.5</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref></td></tr><tr><td align="left" valign="bottom">Romosozumab 210 mg Q1M<break/>→<break/>denosumab 60 mg Q6M</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib61">McClung et al., 2018</xref></td><td align="left" valign="bottom">0.6</td><td align="left" valign="bottom">14.2</td><td align="left" valign="bottom">57.8</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.3</td><td align="left" valign="bottom">6.5</td><td align="left" valign="bottom">15.9</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref></td></tr><tr><td align="left" valign="bottom">Romosozumab 210 mg Q1M<break/>→<break/>placebo</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib61">McClung et al., 2018</xref></td><td align="left" valign="bottom">0.7</td><td align="left" valign="bottom">15.0</td><td align="left" valign="bottom">53.3</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom">0.5</td><td align="left" valign="bottom">10.2</td><td align="left" valign="bottom">18.5</td><td align="left" valign="bottom">—</td><td align="left" valign="bottom"><xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref></td></tr></tbody></table><table-wrap-foot><fn><p>Q, every; M, month; D, day; W, week; BMD, bone mineral density; CTX, C-terminal telopeptide; P1NP, procollagen type 1 amino-terminal propeptide; BSAP, bone-specific alkaline phosphatase.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app3table4" position="float"><label>Appendix 3—table 4.</label><caption><title>Full list of parameters of the core model and the medication extensions.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Parameter</th><th align="left" valign="bottom">Description</th><th align="left" valign="bottom">Value</th><th align="left" valign="bottom">Unit</th><th align="left" valign="bottom">Origin</th><th align="left" valign="bottom">Model equation</th></tr><tr><th align="left" valign="bottom" colspan="6">Core model</th></tr></thead><tbody><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf122"><mml:msub><mml:mi mathsize="90%">ω</mml:mi><mml:msup><mml:mi mathsize="90%" mathvariant="normal">C</mml:mi><mml:mo mathsize="90%" stretchy="false">*</mml:mo></mml:msup></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Reference pre-osteoclast to osteoclast differentiation rate</td><td align="char" char="." valign="bottom">0.93</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf123"><mml:msup><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ11">Equation 10</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf124"><mml:msub><mml:mi mathsize="90%">e</mml:mi><mml:msup><mml:mi mathsize="90%" mathvariant="normal">C</mml:mi><mml:mo mathsize="90%" stretchy="false">*</mml:mo></mml:msup></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Estrogen threshold for downregulation of pre-osteoclast to osteoclast differentiation</td><td align="char" char="." valign="bottom">0.94</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ11">Equation 10</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf125"><mml:msub><mml:mi mathsize="90%">s</mml:mi><mml:msup><mml:mi mathsize="90%" mathvariant="normal">C</mml:mi><mml:mo mathsize="90%" stretchy="false">*</mml:mo></mml:msup></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Sclerostin threshold for upregulation of pre-osteoclast to osteoclast differentiation</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf126"><mml:mrow><mml:mn mathsize="90%">8.60</mml:mn><mml:mo mathsize="90%" stretchy="false">×</mml:mo><mml:msup><mml:mn mathsize="90%">10</mml:mn><mml:mn mathsize="90%">6</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula></td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ11">Equation 10</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf127"><mml:msub><mml:mi mathsize="90%">η</mml:mi><mml:mi mathsize="90%" mathvariant="normal">C</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Reference osteoclast apoptosis rate</td><td align="char" char="." valign="bottom">0.02</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf128"><mml:msup><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ14">Equation 13</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf129"><mml:msub><mml:mi mathsize="90%">e</mml:mi><mml:mi mathsize="90%" mathvariant="normal">C</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Estrogen threshold for upregulation of osteoclast apoptosis</td><td align="char" char="." valign="bottom">0.99</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ14">Equation 13</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf130"><mml:msub><mml:mi mathsize="90%">r</mml:mi><mml:mi mathsize="90%" mathvariant="normal">C</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Resorption signal threshold for upregulation of osteoclast apoptosis</td><td align="char" char="." valign="bottom">10.10</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ14">Equation 13</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf131"><mml:msub><mml:mi mathsize="90%">ν</mml:mi><mml:mi mathsize="90%" mathvariant="normal">C</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Max. rel. effect of regulatory factors on osteoclast apoptosis</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf132"><mml:mrow><mml:mn mathsize="90%">1.23</mml:mn><mml:mo mathsize="90%" stretchy="false">×</mml:mo><mml:msup><mml:mn mathsize="90%">10</mml:mn><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">4</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ14">Equation 13</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf133"><mml:msub><mml:mi mathsize="90%">ω</mml:mi><mml:msup><mml:mi mathsize="90%" mathvariant="normal">B</mml:mi><mml:mo mathsize="90%" stretchy="false">*</mml:mo></mml:msup></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Reference pre-osteoblast to osteoblast differentiation rate</td><td align="char" char="." valign="bottom">0.32</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf134"><mml:msup><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ11">Equation 10</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf135"><mml:msub><mml:mi mathsize="90%">s</mml:mi><mml:msup><mml:mi mathsize="90%" mathvariant="normal">B</mml:mi><mml:mo mathsize="90%" stretchy="false">*</mml:mo></mml:msup></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Sclerostin threshold for downregulation of pre-osteoblast to osteoblast differentiation</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf136"><mml:mrow><mml:mn mathsize="90%">1.63</mml:mn><mml:mo mathsize="90%" stretchy="false">×</mml:mo><mml:msup><mml:mn mathsize="90%">10</mml:mn><mml:mn mathsize="90%">2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula></td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ11">Equation 10</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf137"><mml:msub><mml:mi mathsize="90%">η</mml:mi><mml:mi mathsize="90%" mathvariant="normal">B</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Reference osteoblast apoptosis rate</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf138"><mml:mrow><mml:mn mathsize="90%">8.68</mml:mn><mml:mo mathsize="90%" stretchy="false">×</mml:mo><mml:msup><mml:mn mathsize="90%">10</mml:mn><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf139"><mml:msup><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ14">Equation 13</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf140"><mml:msub><mml:mi mathsize="90%">ω</mml:mi><mml:mi mathsize="90%" mathvariant="normal">B</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Reference osteoblast to osteocyte conversion rate</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf141"><mml:mrow><mml:mn mathsize="90%">6.24</mml:mn><mml:mo mathsize="90%" stretchy="false">×</mml:mo><mml:msup><mml:mn mathsize="90%">10</mml:mn><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">4</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf142"><mml:msup><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ12">Equation 11</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf143"><mml:msub><mml:mi mathsize="90%">η</mml:mi><mml:mi mathsize="90%" mathvariant="normal">Y</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">osteocyte apoptosis rate</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf144"><mml:mrow><mml:mn mathsize="90%">1.10</mml:mn><mml:mo mathsize="90%" stretchy="false">×</mml:mo><mml:msup><mml:mn mathsize="90%">10</mml:mn><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">4</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf145"><mml:msup><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="left" valign="bottom">Estimate</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ15">Equation 14</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf146"><mml:msub><mml:mi mathsize="90%">κ</mml:mi><mml:mi mathsize="90%" mathvariant="normal">s</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Sclerostin degradation rate</td><td align="char" char="." valign="bottom">0.05</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf147"><mml:msup><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="left" valign="bottom">Estimate; see <xref ref-type="bibr" rid="bib90">Suen et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Ominsky et al., 2015</xref>.</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ16">Equation 15</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf148"><mml:msub><mml:mi mathsize="90%">e</mml:mi><mml:mi mathsize="90%" mathvariant="normal">s</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Estrogen threshold for downregulation of sclerostin secretion</td><td align="char" char="." valign="bottom">9.60</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ16">Equation 15</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf149"><mml:msub><mml:mi mathsize="90%">λ</mml:mi><mml:mi mathsize="90%" mathvariant="normal">C</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Reference bone resorption rate per unit density osteoclast</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf150"><mml:mrow><mml:mn mathsize="90%">3.82</mml:mn><mml:mo mathsize="90%" stretchy="false">×</mml:mo><mml:msup><mml:mn mathsize="90%">10</mml:mn><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">6</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf151"><mml:msup><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ17">Equation 16</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf152"><mml:msub><mml:mi mathsize="90%">λ</mml:mi><mml:mi mathsize="90%" mathvariant="normal">B</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Reference bone formation rate per unit density osteoblast</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf153"><mml:mrow><mml:mn mathsize="90%">1.29</mml:mn><mml:mo mathsize="90%" stretchy="false">×</mml:mo><mml:msup><mml:mn mathsize="90%">10</mml:mn><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">6</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf154"><mml:msup><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ17">Equation 16</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf155"><mml:msub><mml:mi mathsize="90%">s</mml:mi><mml:mi mathsize="90%" mathvariant="normal">Ω</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Sclerostin threshold for downregulation of bone formation</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf156"><mml:mrow><mml:mn mathsize="90%">3.04</mml:mn><mml:mo mathsize="90%" stretchy="false">×</mml:mo><mml:msup><mml:mn mathsize="90%">10</mml:mn><mml:mn mathsize="90%">3</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula></td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ17">Equation 16</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf157"><mml:msub><mml:mi mathsize="90%">r</mml:mi><mml:mi mathsize="90%" mathvariant="normal">Ω</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Resorption signal threshold for upregulation of bone formation</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf158"><mml:mrow><mml:mn mathsize="90%">1.02</mml:mn><mml:mo mathsize="90%" stretchy="false">×</mml:mo><mml:msup><mml:mn mathsize="90%">10</mml:mn><mml:mn mathsize="90%">3</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula></td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ17">Equation 16</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf159"><mml:msub><mml:mi mathsize="90%">ν</mml:mi><mml:mi mathsize="90%" mathvariant="normal">Ω</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Max. rel. effect of the resorption signal on bone formation</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf160"><mml:mrow><mml:mn mathsize="90%">1.08</mml:mn><mml:mo mathsize="90%" stretchy="false">×</mml:mo><mml:msup><mml:mn mathsize="90%">10</mml:mn><mml:mn mathsize="90%">2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula></td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ17">Equation 16</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf161"><mml:mi mathsize="90%">γ</mml:mi></mml:math></inline-formula></td><td align="left" valign="bottom">Equilibration rate of the bone mineral content</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf162"><mml:mrow><mml:mn mathsize="90%">6.65</mml:mn><mml:mo mathsize="90%" stretchy="false">×</mml:mo><mml:msup><mml:mn mathsize="90%">10</mml:mn><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf163"><mml:msup><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ18">Equation 17</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf164"><mml:msub><mml:mi mathsize="90%">c</mml:mi><mml:mn mathsize="90%">0</mml:mn></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Reference bone mineral content</td><td align="char" char="." valign="bottom">0.80</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Estimate</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ18">Equation 17</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf165"><mml:msub><mml:mi mathsize="90%">t</mml:mi><mml:mi mathsize="90%" mathvariant="normal">e</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Onset of estrogen decline</td><td align="char" char="." valign="bottom">50.00</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf166"><mml:mi mathsize="90%" mathvariant="normal">y</mml:mi></mml:math></inline-formula></td><td align="left" valign="bottom">Estimate</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ19">Equation 18</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf167"><mml:msub><mml:mi mathsize="90%">τ</mml:mi><mml:mi mathsize="90%" mathvariant="normal">e</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Time scale of estrogen decline</td><td align="char" char="." valign="bottom">2.60</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf168"><mml:mi mathsize="90%" mathvariant="normal">y</mml:mi></mml:math></inline-formula></td><td align="left" valign="bottom">Indep. fit (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1A</xref>)</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ19">Equation 18</xref></td></tr><tr><th align="left" valign="bottom" colspan="6">Bone turnover markers</th></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf169"><mml:msub><mml:mi mathsize="90%">q</mml:mi><mml:mi mathsize="90%">CTX</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Exponent relating the bone resorption rate to CTX levels</td><td align="char" char="." valign="bottom">1.16</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ16">Equation 15</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf170"><mml:msub><mml:mi mathsize="90%">q</mml:mi><mml:mi mathsize="90%">P1NP</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Exponent relating the bone formation rate to P1NP levels</td><td align="char" char="." valign="bottom">1.45</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ16">Equation 15</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf171"><mml:msub><mml:mi mathsize="90%">q</mml:mi><mml:mi mathsize="90%">BSAP</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Exponent relating the bone formation rate to BSAP levels</td><td align="char" char="." valign="bottom">0.92</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ16">Equation 15</xref></td></tr><tr><th align="left" valign="bottom" colspan="6">Medication extension: sclerostin antibodies</th></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf172"><mml:msub><mml:mi mathsize="90%">E</mml:mi><mml:mi mathsize="90%">blosozumab</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Efficacy: blosozumab</td><td align="char" char="." valign="bottom">0.01</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ22">Equation 21</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf173"><mml:msub><mml:mi mathsize="90%">T</mml:mi><mml:mi mathsize="90%">blosozumab</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Effective half-life: blosozumab</td><td align="char" char="." valign="bottom">7.00</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf174"><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf175"><mml:msub><mml:mi mathsize="90%">T</mml:mi><mml:mi mathsize="90%">romosozumab</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ22">Equation 21</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf176"><mml:msub><mml:mi mathsize="90%">E</mml:mi><mml:mi mathsize="90%">romosozumab</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Efficacy: romosozumab</td><td align="char" char="." valign="bottom">0.01</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf177"><mml:msub><mml:mi mathsize="90%">E</mml:mi><mml:mi mathsize="90%">blosozumab</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ22">Equation 21</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf178"><mml:msub><mml:mi mathsize="90%">T</mml:mi><mml:mi mathsize="90%">romosozumab</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Effective half-life: romosozumab</td><td align="char" char="." valign="bottom">7.00</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf179"><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi></mml:math></inline-formula></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib87">Solling et al., 2018</xref></td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ22">Equation 21</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf180"><mml:msub><mml:mi mathsize="90%">δ</mml:mi><mml:mi mathsize="90%" mathvariant="normal">s</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Sclerostin/antibody unbinding rate</td><td align="char" char="." valign="bottom">0.05</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf181"><mml:msup><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf182"><mml:msub><mml:mi mathsize="90%">κ</mml:mi><mml:mi mathsize="90%" mathvariant="normal">s</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ27">Equation 25</xref></td></tr><tr><th align="left" valign="bottom" colspan="6">Medication extension: RANKL antibodies</th></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf183"><mml:msub><mml:mi mathsize="90%">E</mml:mi><mml:mi mathsize="90%">denosumab</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Efficacy: denosumab</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf184"><mml:mrow><mml:mn mathsize="90%">4.34</mml:mn><mml:mo mathsize="90%" stretchy="false">×</mml:mo><mml:msup><mml:mn mathsize="90%">10</mml:mn><mml:mn mathsize="90%">3</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula></td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ22">Equation 21</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf185"><mml:msub><mml:mi mathsize="90%">T</mml:mi><mml:mi mathsize="90%">denosumab</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Effective half-life: denosumab</td><td align="char" char="." valign="bottom">10.00</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf186"><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi></mml:math></inline-formula></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib4">Bekker et al., 2004</xref></td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ22">Equation 21</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf187"><mml:msubsup><mml:mi mathsize="90%">β</mml:mi><mml:msup><mml:mi mathsize="90%" mathvariant="normal">C</mml:mi><mml:mo mathsize="90%" stretchy="false">*</mml:mo></mml:msup><mml:mi mathsize="90%">rAb</mml:mi></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="bottom">Max. rel. effect of RANKL antibodies on pre-osteoclast to osteoclast differentiation</td><td align="char" char="." valign="bottom">0.87</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ26">Equation 24</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf188"><mml:msubsup><mml:mi mathsize="90%">β</mml:mi><mml:mi mathsize="90%" mathvariant="normal">b</mml:mi><mml:mi mathsize="90%">rAb</mml:mi></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="bottom">Max. rel. effect of RANKL antibodies on mineralization</td><td align="char" char="." valign="bottom">0.02</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ26">Equation 24</xref></td></tr><tr><th align="left" valign="bottom" colspan="6">Medication extension: bisphosphonates</th></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf189"><mml:msub><mml:mi mathsize="90%">E</mml:mi><mml:mi mathsize="90%">alendronate</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Efficacy: alendronate</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf190"><mml:mrow><mml:mn mathsize="90%">2.97</mml:mn><mml:mo mathsize="90%" stretchy="false">×</mml:mo><mml:msup><mml:mn mathsize="90%">10</mml:mn><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ24">Equation 22</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf191"><mml:msub><mml:mi mathsize="90%">T</mml:mi><mml:mi mathsize="90%">alendronate</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Effective half-life: alendronate</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf192"><mml:mrow><mml:mn mathsize="90%">1.53</mml:mn><mml:mo mathsize="90%" stretchy="false">×</mml:mo><mml:msup><mml:mn mathsize="90%">10</mml:mn><mml:mn mathsize="90%">2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf193"><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi></mml:math></inline-formula></td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ24">Equation 22</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf194"><mml:msubsup><mml:mi mathsize="90%">η</mml:mi><mml:mi mathsize="90%" mathvariant="normal">C</mml:mi><mml:mi mathsize="90%">bp</mml:mi></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="bottom">Max. contribution of bisphosphonates to osteoclast apoptosis rate</td><td align="char" char="." valign="bottom">1.00</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf195"><mml:msup><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi><mml:mrow><mml:mo mathsize="90%" stretchy="false">-</mml:mo><mml:mn mathsize="90%">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ28">Equation 26</xref></td></tr><tr><th align="left" valign="bottom" colspan="6">Medication extension: PTH analogs</th></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf196"><mml:msub><mml:mi mathsize="90%">E</mml:mi><mml:mi mathsize="90%">teriparatide</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Efficacy: teriparatide</td><td align="char" char="." valign="bottom">0.27</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ24">Equation 22</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf197"><mml:msub><mml:mi mathsize="90%">T</mml:mi><mml:mi mathsize="90%">teriparatide</mml:mi></mml:msub></mml:math></inline-formula></td><td align="left" valign="bottom">Effective half-life: teriparatide</td><td align="char" char="." valign="bottom">0.04</td><td align="left" valign="bottom"><inline-formula><mml:math id="inf198"><mml:mi mathsize="90%" mathvariant="normal">d</mml:mi></mml:math></inline-formula></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib81">Satterwhite et al., 2010</xref></td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ24">Equation 22</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf199"><mml:msubsup><mml:mi mathsize="90%">β</mml:mi><mml:mi mathsize="90%" mathvariant="normal">B</mml:mi><mml:mi mathsize="90%">pth</mml:mi></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="bottom">Max. rel. effect of PTH analogs on osteoblast apoptosis</td><td align="char" char="." valign="bottom">1.31</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ29">Equation 27</xref></td></tr><tr><td align="left" valign="bottom"><inline-formula><mml:math id="inf200"><mml:msubsup><mml:mi mathsize="90%">β</mml:mi><mml:msup><mml:mi mathsize="90%" mathvariant="normal">C</mml:mi><mml:mo mathsize="90%" stretchy="false">*</mml:mo></mml:msup><mml:mi mathsize="90%">pth</mml:mi></mml:msubsup></mml:math></inline-formula></td><td align="left" valign="bottom">Max. rel. effect of PTH analogs on pre-osteoclast to osteoclast differentiation</td><td align="char" char="." valign="bottom">4.28</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Calibration</td><td align="left" valign="bottom"><xref ref-type="disp-formula" rid="equ29">Equation 27</xref></td></tr></tbody></table><table-wrap-foot><fn><p>CTX, C-terminal telopeptide; P1NP, procollagen type 1 amino-terminal propeptide; BSAP, bone-specific alkaline phosphatase; PTH, parathyroid hormone.</p></fn></table-wrap-foot></table-wrap><fig id="app3fig1" position="float"><label>Appendix 3—figure 1.</label><caption><title>Calibration datasets comparing model predictions and clinical data from various studies.</title><p>All conventions identical to <xref ref-type="fig" rid="fig2">Figure 2</xref>. Drug administrations are provided in the bottom row. See <xref ref-type="table" rid="app3table2">Appendix 3—table 2</xref> for a list of data sources and <xref ref-type="table" rid="app3table3">Appendix 3—table 3</xref> for goodness-of-fit measures. Dosing: mg, milligrams; mcg, micrograms; Q <inline-formula><mml:math id="inf201"><mml:mi>x</mml:mi></mml:math></inline-formula> M, dose administered every <inline-formula><mml:math id="inf202"><mml:mi>x</mml:mi></mml:math></inline-formula> months; Q <inline-formula><mml:math id="inf203"><mml:mi>x</mml:mi></mml:math></inline-formula> W, every <inline-formula><mml:math id="inf204"><mml:mi>x</mml:mi></mml:math></inline-formula> weeks; Q <inline-formula><mml:math id="inf205"><mml:mi>x</mml:mi></mml:math></inline-formula> D, every <inline-formula><mml:math id="inf206"><mml:mi>x</mml:mi></mml:math></inline-formula> days; B, blosozumab; A, alendronate; D, denosumab; T, teriparatide.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-76228-app3-fig1-v1.tif"/></fig></sec></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.76228.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Napoli</surname><given-names>Nicola</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gqx4x78</institution-id><institution>Campus Bio-Medico University of Rome</institution></institution-wrap><country>Italy</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2021.12.17.473190" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2021.12.17.473190"/></front-stub><body><p>The authors have developed a mathematical framework of drug interventions for postmenopausal osteoporosis using bisphosphonates, parathyroid hormone analogs, romosozumab, and denosumab. After calibrating and validating the model, authors demonstrated a predictive ability for complex clinical scenarios including sequential and parallel drug combinations. These data may be of great help in clinical practice.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.76228.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Napoli</surname><given-names>Nicola</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gqx4x78</institution-id><institution>Campus Bio-Medico University of Rome</institution></institution-wrap><country>Italy</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Pivonka</surname><given-names>Peter</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03pnv4752</institution-id><institution>Queensland University of Technology</institution></institution-wrap><country>Australia</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.12.17.473190">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.12.17.473190v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Modeling osteoporosis to design and optimize pharmacologic therapies comprising multiple drug types&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 1 peer reviewer, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Peter Pivonka (Reviewer #1).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>(1) The discussion needs a lot of revision: it must be clear to authors that the manuscript will be read also by a lot of physicians and a clear, clinical language should be used.</p><p>(2) In terms of bone density measurements authors should compare their data with those from Black et al., (JBMR 2018) from the SOF study and Dr Ensrud (JCEM 2022).</p><p>The paper is very well written and presents promising results.</p><p>The introduction is very comprehensive.</p><p>The only additional reference I would suggest is:</p><p>Lavaill et al., 2021 &quot;Effects of PTH treatment in osteoporosis – insights from a mechanistic PK-PD model, BMMB, pp1-16, 2020.&quot; (https://doi.org/10.1007/s10237-020-01307-6)</p><p>This paper explores the synergy between exercise and PTH treatment which is essentially a combined treatment. This would be one of the few papers that could be used in the Discussion section as comparison with the current results / model developments.</p><p>Sentence containing &quot;(BMD) in specific bone types&quot;;</p><p>I suggest substituting &quot;types&quot; with &quot;site&quot; as you refer to hip, wrist, vertebra BMD.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.76228.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>(1) The discussion needs a lot of revision: it must be clear to authors that the manuscript will be read also by a lot of physicians and a clear, clinical language should be used.</p></disp-quote><p>We appreciate the comment as it is our goal to make the manuscript as readable as possible for a large interdisciplinary audience. In response, in the revised manuscript, we have extensively revised the Discussion section, placing special emphasis on the clinical relevance of our findings and avoiding modelling-related jargon as much as possible. Also, in response to point 2, we have added a paragraph on how our findings can be related to fracture risk reduction, the prime clinical goal of osteoporosis therapy (see response below). Since there are many changes which affect the Discussion section as a whole, we refrain from listing each individual change here.</p><disp-quote content-type="editor-comment"><p>(2) In terms of bone density measurements authors should compare their data with those from Black et al., (JBMR 2018) from the SOF study and Dr Ensrud (JCEM 2022).</p></disp-quote><p>We thank the Reviewer for pointing us to the papers by Black et al., (JBMR 33, 389, 2018) and Ensrud et al., (JCEM, <italic>dgac324</italic>, 2022).</p><p>First, we would like to recall that our model predicts the time course of the bone mineral density (BMD) for a given drug treatment or ageing scenario. In contrast, the publications by Black et al., and Ensrud et al., report fracture predictions based on BMD measurements. Relating BMD time courses generated by our model to fracture risk would require an additional (statistical) model that depends on details of the target demographic (as does the well-known FRAX tool, which is region-dependent and takes into account a variety of non-BMD related risk factors). This however is a major independent modelling effort and goes beyond the scope of the current approach. However, we believe that the above references (as well as other seminal studies relating BMD and fracture risk) are a perfect occasion to discuss the possibility of creating such a statistical model. In the Discussion section of the revised manuscript, we have therefore included the following new part:</p><p>“Clearly, the goal of osteoporosis therapy is the reduction of fracture risk during and after therapy. While BMD has a prime role in the evaluation of osteoporosis therapies and can be measured rather easily using dual-energy x-ray absorptiometry (DXA), its relationship to fracture risk is complex. Fracture risk calculations used in clinical practice also involve demographic and lifestyle-related factors while mostly relying on BMD point measurements (Kanis et al., Bone 44, 2009). However, the quantitative associations between BMD, age and fracture risk reported in many studies (Kanis et al., Osteoporos. Int. 12, 2001; Berger et al., JBMR 24, 2009; Austin et al., JBMR 27, 2012; Krege et al., BoneKEy Rep. 2, 2013; Black et al., JBMR 33, 2018; Ensrud et al., JCEM 2022) can be used to create statistical models that may relate entire BMD time courses to a patient’s fracture risk. Combining such statistical models with the physiology-based model presented here would enable to optimize therapies directly for a minimized long-term fracture risk instead of maximized BMD gain.”</p><disp-quote content-type="editor-comment"><p>The paper is very well written and presents promising results.</p><p>The introduction is very comprehensive.</p></disp-quote><p>We thank the Reviewer for the positive assessment of our manuscript.</p><disp-quote content-type="editor-comment"><p>The only additional reference I would suggest is:</p><p>Lavaill et al., 2021 “Effects of PTH treatment in osteoporosis – insights from a mechanistic PK-PD model, BMMB, pp1-16, 2020.” (https://doi.org/10.1007/s10237-020-01307-6)</p><p>This paper explores the synergy between exercise and PTH treatment which is essentially a combined treatment. This would be one of the few papers that could be used in the Discussion section as comparison with the current results / model developments.</p></disp-quote><p>We thank the Reviewer for pointing us towards this paper. Indeed, physical activity is an important contributor to bone remodelling. As our current model focuses exclusively on pharmacologic treatments and does not capture biomechanical feedback, a direct comparison of results with those by Lavaill et al., is not possible. Nevertheless, the perspective of including the effects of physical activity in an integrated modelling framework is attractive both from a modelling and a therapy standpoint. In the revised discussion, we have therefore added a part highlighting the possible role of physical activity on osteoporosis therapy:</p><p>“Physical activity is another important contributor to bone remodeling, which we have not considered here. Detailed modeling approaches involving biomechanical feedback suggest synergistic effects between drug treatment of osteoporosis and physical activity (Lavaill et al., BMMB 19, 2020). Such results call for a further exploration of integrated approaches to osteoporosis treatment combining pharmacologic therapy and lifestyle adjustments.”</p><p>We also mention the work in the introduction, where we discuss previous modelling of combination therapies.</p><disp-quote content-type="editor-comment"><p>Sentence containing &quot;(BMD) in specific bone types&quot;;</p><p>I suggest substituting &quot;types&quot; with &quot;site&quot; as you refer to hip, wrist, vertebra BMD.</p></disp-quote><p>We agree with the suggestion and have made the corresponding change in the revised manuscript.</p><p>In our initial response to the Public Review, we also promised to describe better the rationale behind the simplified pharmacokinetic description of the various drug classes captured by the model. In the revised manuscript, we have modified and extended the following part in the beginning of Appendix B:</p><p>“We include a dynamic description of several drug classes through separate model extensions, which depend on the functional drug concentration. The pharmacodynamic description is drug-specific and represents the individual mechanism of action of the respective drug class. For the pharmacokinetic description of each drug, we resort to simple first-order kinetics with drug-specific half-lives, which reduces the amount of model parameters. More detailed pharmacokinetic descriptions involve drug absorption and transfer between different body compartments, depending on the route of administration (oral, intravenous or subcutaneous). However, simulations of the calibrated model demonstrate that first-order kinetics yields an effective approximation of the pharmacokinetic features essential to capture a drug's long-term effects on bone remodeling, as suggested by comparisons of simulated and measured BTM concentrations (Supplementary Figures 2 and 3).”</p></body></sub-article></article>